Unexpected “Harmless” Microorganisms May Significantly Influence Colorectal Cancer

Posted on July 3, 2025 by Igor Mitreski

Methanobrevibacter shows that a microorganism named smithii is linked to colorectal cancer

Kateryna Kon/Science Photo Library/Alamy

Ancient mysterious microorganisms, distinct from bacteria and viruses, are believed to have a role in colorectal cancer, challenging the notion that these microorganisms are harmless.

Life can be categorized into three domains: the first consists of single-celled bacteria, the second includes eukaryotes—multicellular organisms such as animals and plants equipped with complex cells housing nuclei and DNA.

The third domain is Archaea, comprising single-celled organisms previously mistaken for bacteria due to their lack of nuclei. Recent findings reveal that they possess some traits similar to eukaryotes, suggesting that the first eukaryotes might have originated from archaeal cells that incorporated free-living bacteria.

Our intestines harbor trillions of bacteria and viruses linked to various conditions, including cancer, diabetes, obesity, and heart disease, alongside archaea, though the latter is often overlooked.

“Most researchers studying the human microbiome tend to overlook archaea, disregarding their potential significance,” notes Roxy Mohammadzadeh from Glaz Medical College in Austria. However, several archaea have been associated with colorectal cancer, Parkinson’s disease, infections related to gum disease, and urinary tract infections.

In pursuit of a clearer understanding, Mohammazzade and her team analyzed data from 19 clinical studies involving more than 1800 individuals.

They observed that while the link between archaea and several medical conditions is prevalent, it varies. Particularly, Methanobrevibacter smithii was notably present in individuals with colorectal cancer. This microbe significantly aids digestion by converting bacterial fermentation byproducts like hydrogen and carbon dioxide into methane.

Utilizing microbial culturing techniques, the team found M. smithii interacting with bacteria such as Bacteroides fragilis, E. coli, and Fusobacterium nucleatum.

These bacterial species have been linked to colorectal cancer; particularly, the association with F. nucleatum appears to be significant given its relationship with cancer. When M. smithii coexists with F. nucleatum, the latter produces higher amounts of succinate, a critical metabolic signaling molecule recognized for enhancing tumor invasiveness and spread potential noted in cancer studies.

“This represents the first mechanical evidence linking archaea to human diseases, particularly colorectal cancer,” states Mohamatzade.

This research reinforces earlier findings connecting M. smithii to colorectal cancer, asserting the need for further exploration to uncover the mechanisms at play and why this microorganism is prevalent in colorectal cancer patients, according to Gianmarco Piccinno from Trent University, Italy. He emphasizes that most available evidence is correlational and calls for additional studies.

“While Archaea is acknowledged as part of the human microbiota, its direct involvement in diseases remains poorly understood,” points out Sunny Wong from Nanyang Technological University in Singapore. Recent studies have also established connections between archaea and colorectal cancer. “Though they exist in fewer numbers than bacteria in the intestine, they are metabolically active, often consuming hydrogen, producing methane, and interacting with the host.”

Topic:

Source: www.newscientist.com

Gastric Bypass Surgery Potentially Lowers Intestinal Cancer Risk

Posted on June 26, 2025 by Igor Mitreski

Gastric bypass surgery is primarily utilized for weight loss, but it may provide other advantages

Portra/Getty Images

A widely recognized form of weight loss surgery may lower the risk of colorectal cancer by changing the levels of bile acids in the bloodstream. These findings could pave the way for new bowel cancer treatments.

During gastric bypass surgery, the stomach is surgically altered to create a small upper pouch and a larger lower pouch. The small intestine is then connected to the upper pouch, allowing food and digestive juices to bypass most of the upper stomach and small intestine. Post-surgery, patients often feel fuller and experience quicker weight loss.

Earlier research indicated that this procedure is associated with a decreased risk of colorectal cancer; however, the underlying reasons remained unclear. To investigate further, Rebecca Kesselling of the University of Freiburg, Germany, and her team fed mice a high-fat diet until they reached approximately 50% of their starting weight. They then performed a partial gastric bypass on some of the mice, while the remaining mice underwent a sham surgery that did not alter their digestive systems.

To isolate the weight-loss effects of gastric bypass surgery, the team grouped the gastric bypass mice alongside half of the sham-operated mice. Over six weeks, the gastric bypass mice lost about 20% of their body weight on average.

Subsequently, the researchers implanted colorectal cancer cells into the colons of the mice. After an additional six weeks, it was observed that colon tumors in the gastric bypass mice were two-thirds smaller than those in the mice that either continued gaining weight or lost weight solely through diet.

Additionally, cancer spread to the liver was seen in only one out of twenty gastric bypass mice, while it occurred in most of the sham-operated mice.

“Both sham groups exhibited similar tumor levels, but weight loss alone could not account for the lower cancer risk, suggesting that gastric bypass involves additional factors,” Kesselling explains.

The researchers speculated that this might be attributed to alterations in bile acids, which are compounds that aid in fat digestion. These molecules are typically produced by the liver, move through the gallbladder, stomach, and small intestine, and then return to the liver via the bloodstream.

“Bile acids are reintroduced into the small intestine during bypass surgery,” Kesselling states, implying that this process may lead to variations in intestinal bacteria that chemically modify these molecules.

The mice that underwent gastric bypass surgery displayed lower levels of specific bile acids, known as primary bile acids, in both their colon and bloodstream compared to the sham group.

To further explore whether changes in bile acids influenced cancer risk, the team conducted a similar experiment with another group of mice. Instead of gastric bypass, these mice had surgery that redirected bile acids to the latter part of the small intestine without altering the stomach.

Significantly, the team noted that this surgery also lowered primary bile acid levels in the bloodstream and decreased the size and spread of colorectal tumors as effectively as gastric bypass surgery. This was supported by an additional experiment, where they identified that primary bile acids promote the growth of colorectal cancer cells in laboratory settings.

The results indicate that focusing on primary bile acids may hold promise for cancer treatment. “We might be able to leverage various oral medications designed to reduce these bile acids to replicate some of the advantageous effects of gastric bypass surgery,” notes Vance Albaf from Louisiana State University.

Topic:

Source: www.newscientist.com

Cancer Cells Hijack Mitochondria from Neurons to Fuel Their Growth

Posted on June 25, 2025 by Igor Mitreski

Neurons Growing Among Cancer Cell Cultures (Stained Green)

Simon Grelet and Gustavo Ayala

Cancer cells are known to hijack energy-generating components from neurons, facilitating their spread to remote locations. This groundbreaking discovery may enhance treatments for the most aggressive tumors.

“This marks the first instance of mitochondrial transfer from nerves to cancer cells,” states Elizabeth Lepasky, who is not directly linked to the study conducted at the Roswell Park Comprehensive Cancer Center in Buffalo, New York. “This signifies a pivotal advancement in cancer neuroscience, a rapidly evolving field.”

Prior knowledge indicated that both intratumor and adjacent tumors produce proteins and electrical impulses that promote cancer growth and dissemination. “A higher density of nerves within tumors correlates with a poorer prognosis,” says Simone Grelet from the University of Southern Alabama.

Earlier investigations have demonstrated that brain tumor cells can absorb mitochondria (the energy-producing organelles) from non-neuronal brain cells. However, the potential for tumor cells to extract mitochondria from neurons remained unclear, according to Grelet.

To explore this, Grelet and his team genetically modified breast cancer cells derived from mice to contain red fluorescent molecules and combined them with mouse neurons that had mitochondria labeled with green pigments in laboratory conditions. Imaging revealed that cancer cells can seize mitochondria from neurons within a matter of hours.

“Cancer cells extend their membranes to absorb mitochondria from neurons,” explains Grelet. “It’s akin to a lineup of mitochondria filtering through a narrow passage, entering the cancer cells sequentially.”

To assess whether this phenomenon occurs in vivo, the researchers injected red breast cancer cells into the mammary glands of female mice to induce tumor growth. They also genetically engineered the surrounding nerves to carry green mitochondria. Approximately one month later, 2% of the cancer cells in these tumors had taken up mitochondria from neurons.

Conversely, 14% of tumor cells that metastasized to the brain exhibited neuronal-derived mitochondria. This suggests that cancer cells acquiring mitochondria from nerves have a significant advantage over other cancer types. Further tests indicate that these mitochondria contribute to greater resilience against the physical and chemical challenges encountered in the bloodstream.

“Cancer cells face numerous hurdles in their migration,” remarks Repasky. “They must escape the primary tumor, navigate barriers to blood vessels, exit the bloodstream, and secure sufficient oxygen and nutrients at secondary sites. By appropriating mitochondria, it appears cancer cells can endure this tumultuous journey,” she adds.

To determine if this process also occurs in humans, researchers examined tumor samples from eight women with metastatic breast cancer. They discovered that tumor cells from distant sites contained, on average, 17% more mitochondria compared to those from breast tumors, suggesting that similar mechanisms are at play in patients, according to Grelet.

Moreover, the team analyzed human prostate tumor samples and observed that cancer cells near nerves contained significantly more mitochondria than those situated further away. “I believe this represents a common mechanism utilized by various tumor types,” asserts team member Gustavo Ayala from the University of Texas Health Science Center in Houston.

The findings indicate that inhibiting mitochondrial transfer could potentially curtail the spread of the deadliest tumors. “We are optimistic that this is achievable, at least for certain tumor types,” Repasky suggests. Ayala mentions that they are working towards developing a drug to facilitate this approach.

Topic:

Source: www.newscientist.com

CAR T-Cell Therapy Can Be Administered to Cancer Patients

Posted on June 19, 2025 by Igor Mitreski

Illustration of CAR T-cell therapy targeting multiple myeloma, a type of blood cancer

Nemes Laszlo/Alamy

CAR T-cell therapy has the potential to transform cancer treatment. This innovative treatment genetically alters immune cells to combat diseases but is both complex and costly. Researchers have recently achieved the ability to develop personalized therapies within the bodies of non-human animals.

This form of treatment is primarily accessible in the UK and the US for select patients with various blood cancers, such as certain leukemias, where B cells—crucial immune components—grow uncontrollably. The process entails extracting T cells from a patient’s blood, genetically modifying them to target and destroy B cells, then duplicating and reintroducing these modified cells back into the patient’s body.

Nonetheless, this method is time-intensive. “You need to take the blood and send it to the Central Manufacturing Institute before it can be returned,” explains Carl June from the University of Pennsylvania. “This makes scaling the process challenging.” Additionally, the treatment comes at a steep price: over $500,000 per patient.

In search of a more efficient method, June and his team focused on gene molecules that deliver instructions to produce proteins that target B cells. They encapsulated these molecules in fat droplets, allowing entry into T cells, where they can identify and eliminate B cells. However, this effect is temporary, as the RNA code degrades within a week.

The researchers injected cancerous human B cells and healthy T cells into mice lacking an immune system. After a week, they administered five fat droplets to these mice over a span of two weeks, with some receiving higher doses.

Three weeks later, the mice that received the highest dose displayed no detectable tumor cells and no side effects. “The level of tumor cells was as minimal as we could measure,” remarks June.

The team also administered fat droplets to 22 healthy monkeys, resulting in the production of CAR T cells within their bodies and completely eradicating all B cells within just one day. Although B cells are essential for antibody production, the treatment was well tolerated by all but one monkey, which experienced a severe inflammatory response.

“This is truly remarkable,” says Karin Straathof from University College London. This could represent a significantly easier and more affordable method for implementing CAR T-cell therapy, she asserts.

However, one downside of standard CAR T-cell therapies is their ability to provide long-lasting protection, notes Straathof. The newly developed technique temporarily produces these cells; if cancer returns, additional treatments will be necessary. Furthermore, the effectiveness and safety of this approach in humans remain unverified, pending clinical trials.

June confirms that the team is currently testing the method in healthy humans. “The first patient was treated in the past few weeks,” he states.

Topic:

Source: www.newscientist.com

Researchers Utilize Enhanced DNA Techniques to Classify Breast Cancer

Posted on June 12, 2025 by Igor Mitreski

Triple-negative breast cancer (TNBC) is recognized as one of the more aggressive and challenging breast cancers to treat. Lacking the three standard hormonal markers associated with estrogen receptors, progesterone receptors, and HER2, this absence complicates the selection of effective treatment strategies for healthcare providers.

Researchers characterize TNBC as a collection of various diseases with distinct molecular characteristics that impact how the cancer manifests and its response to treatments. They utilize specific genes and gene products to categorize TNBC types. It is important to note that there are overlaps in the current classifications, which might be explained by the presence and levels of particular chemical molecules on the DNA. These molecules play a role in regulating whether genes are activated or deactivated in cells through processes known as DNA methylation.

In this study, researchers from Sweden explored how the distribution and patterns of DNA methylation delineate different forms of TNBC, influencing tumor behavior and interactions with the body’s immune system and its treatment responses. They analyzed 235 tumor samples from various patients in Sweden, ensuring that the data was refined to focus solely on cancerous cells rather than healthy tissue.

Employing a statistical technique known as Non-negative matrix factorization, they identified two primary categories of TNBC based on DNA methylation patterns: basal and nonbasal groups. This categorization aligns with previous classifications grounded in how cells interpret gene functions, termed gene expression. The basal group comprised tumors that were typically more active in immune responses and had a higher incidence of mutations linked to DNA repair issues, notably involving the common BRCA1 gene. Conversely, although the nonbasal group lacked hormone receptors, they exhibited increased activity in genes that influence hormonal responses.

Utilizing statistical assessments, the researchers subdivided each major group into smaller subtypes. Within the basal tumors, they identified three subgroups, referred to as basal1, basal2, and basal3, characterized by varying levels of immune cell activity and gene expression profiles. One specific subgroup, Basal3, demonstrated elevated expression of proteins that aid tumors in evading the immune system. The researchers found that specific DNA methylation patterns could activate or deactivate these proteins, indicating that patients with basal tumors might benefit from existing cancer treatments targeting this protein. The Basal2 subgroup expressed genes that inhibit immune activity, while the Basal1 subgroup displayed no significant immune-related behavior.

In the nonbasal category, researchers distinguished two subtypes: nonbasal1 and nonbasal2. Both of these subgroups were more prevalent among older patients and exhibited lower survival rates compared to the basal subgroup. The Nonbasal2 group encompassed tumors that influenced hormonal activity and responses to fatty treatments, whereas the Nonbasal1 group experienced more frequent disruptions in genes associated with tumor suppression.

Across all groups, researchers identified numerous genes whose methylation could modulate tumor growth and responses to the surrounding environment. To validate their findings in a broader context, they sourced independent tumor datasets from global databases and conducted similar classification analyses. They confirmed that the identified methylation subtypes appeared in other TNBC samples and correlated methylation patterns with tumor defense mechanisms, pinpointing strategies TNBC tumors may utilize to evade the immune system.

The researchers also acknowledged several limitations of their study. Their focus on DNA methylation represents just one of many chemical modifications that can influence TNBC behavior. Some of the independent datasets utilized originated from general breast cancer studies and were not exclusively focused on TNBC. Additionally, a significant portion of the data came from Western and Northern European populations, which may limit the applicability of the findings to individuals from other ethnicities. They emphasized the necessity for larger and more diverse datasets to gain a comprehensive understanding of TNBC subtypes.

In conclusion, the researchers posited that examining DNA methylation in patient samples could effectively categorize TNBC into meaningful subtypes, each with unique biological features, immune environments, and potential treatment responses. They recommended that future studies explore the origins of epigenetic modifications, such as DNA methylation, and how these alterations contribute to variations in TNBC subtypes.

Post view: 228

Source: sciworthy.com

New AI Tools Predict Which Men Will Respond to Prostate Cancer Treatments

Posted on May 30, 2025 by Igor Mitreski

Medical professionals have created an artificial intelligence tool capable of predicting which men diagnosed with prostate cancer are likely to benefit from treatment, potentially lowering the risk of mortality.

Abiraterone is regarded as a revolutionary treatment for the condition, which is the most prevalent cancer among men in over 100 countries. It has already enabled countless individuals with advanced prostate cancer to enjoy extended lifespans.

Nonetheless, some nations, including the UK, have ceased offering this “remarkable” medication to men whose cancer has not metastasized.

Currently, teams from the US, UK, and Switzerland are developing AI assessments that determine which men are likely to gain from Abiraterone. This “promising” advancement enhances the healthcare system to allocate medications more effectively to suitable candidates while allowing others to avoid unnecessary treatments.

The AI test was unveiled in Chicago at the annual conference of the American Society of Clinical Oncology, the largest cancer conference globally.

Nick James, a professor specializing in prostate and bladder cancer research at the London Cancer Institute, serves as a consultant clinical oncologist at the Royal Marsden NHS Foundation Trust, where he leads the development team.

“Abiraterone has already greatly enhanced the prognosis for hundreds of thousands of men with advanced prostate cancer,” James stated. “We recognize that for many men whose cancer hasn’t spread yet, it can have significant implications.

“However, the treatment comes with side effects and necessitates additional monitoring for potential issues such as hypertension or liver abnormalities. It is extremely valuable to identify those most likely to truly benefit, as it may slightly elevate the risks of diabetes and heart complications.

“This research indicates that those who respond optimally to abiraterone, as well as those who fare well with standard treatments alone, can decide between hormone therapy and radiation therapy.”

The AI tool examines tumor images and identifies features that may not be discernible to the naked eye. Prostate Cancer UK, the Medical Research Council, and arterial funded teams analyzed biopsy images from over 1,000 men exhibiting high-risk prostate cancer that had not metastasized.

AI analysis pinpointed 25% of the men in the study who were most likely to gain from Abiraterone. For these individuals, the medication halved the risk of mortality.

In the study, patients received a score indicating a positive or negative biomarker. This was then compared with outcomes. Among those with biomarker-positive tumors, the risk of death was reduced from 17% to 9% after five years for one in four men.

For patients with biomarker-negative tumors, Abiraterone decreased the risk of death from 7% to 4%. The research team indicated this result was neither statistically nor clinically significant, meaning these men are better off with standard treatment alone and can avoid unnecessary therapies.

Skip past newsletter promotions

Professor Gert Attard, the research co-leader at UCL Cancer Institute, noted, “This study highlights that, within a sizable cohort of patients, new algorithms can be utilized to glean information from routinely available pathology slides to customize treatments to individual patients, thereby minimizing unnecessary interventions while maximizing the effectiveness of treatment.”

James mentioned that fewer men may require the medication than previously believed, suggesting that health services should contemplate administering it to men whose cancer hasn’t spread.

While it has been sanctioned for use within the NHS for advanced prostate cancer in England, it has yet to receive approval for newly diagnosed high-risk cases that have not metastasized. However, men with indications of high-risk cancer have had access to treatment in Scotland and Wales for two years.

“Abiraterone costs just £77 per pack compared to thousands for new treatments,” James remarked. “We sincerely hope this new research will clarify who truly benefits from this drug, especially given NHS England’s decision not to fund it for high-risk non-metastatic prostate cancer cases.”

Dr. Matthew Hobbs, research director at Prostate Cancer UK, termed the AI test as “promising.” He further elaborated:

Source: www.theguardian.com

Enhanced Cancer Screening Could Detect Early Cases in Women with Dense Breasts

Posted on May 22, 2025 by Igor Mitreski

High-density breast tissue and tumors resemble each other on scans.

Golodenkov/Shutterstock

Recent research indicates that those with dense breast tissue may gain from an additional round of cancer screening, as a significant trial uncovered tumors that were overlooked in standard mammograms.

In the UK, mammograms—an x-ray scan used for breast cancer screening—are provided for individuals aged 50 to 71. These scans look for white spots that indicate cancer presence. However, around 50% of women in this age range have dense breasts, characterized by a high amount of fibrous and glandular tissue, also appearing white on the scans. This similarity complicates tumor detection.

“The challenge with dense breasts is that cancers may go unnoticed until they grow significantly large, which negatively affects prognosis,” said Thomas Hervich, who wasn’t a part of the study at the Medical University of Vienna in Austria.

To determine whether additional screenings can help, Sarah Vinnicombe and her colleagues at the University of Dundee recruited over 6,000 women aged 50-70 from across the UK. Participants were randomly divided into three groups, each receiving extra screening through advanced x-ray methods such as MRI, ultrasound, or contrast-enhanced mammography.

In this extended screening phase, MRI and contrast-enhanced mammography together identified 85 small tumors—three times as many as detected by ultrasound. Twelve of these tumors were located in milk ducts, suggesting a lower likelihood of spreading beyond the breast. Conversely, the other 73 tumors were invasive, increasing the risk that cancer could migrate into surrounding breast tissue and beyond.

“Detecting these cancers is crucial. They typically grow over time, and finding them within three to four years can lead to larger sizes,” stated Hervich. “Some tumors are aggressive, so I believe supplemental screening could save lives.”

However, it’s uncertain if this will hold true. For instance, a 2021 trial on ovarian cancer screening revealed a decrease in cases but did not correlate with increased longevity. Additionally, some tumors detected may not be cancerous or aggressive. Thus, unnecessary screening could lead to undue anxiety and treatment.

The researchers plan to continue monitoring participants to assess whether supplementary screenings result in saved lives.

topic:

Source: www.newscientist.com

Factors That Truly Influence Your Prostate Cancer Risk

Posted on May 21, 2025 by Igor Mitreski

Prostate cancer is the most prevalent cancer among men, with roughly one in eight men receiving a diagnosis in their lifetime. Nevertheless, not all prostate cancers are life-threatening; in fact, many develop slowly and remain harmless.

“There are essentially two categories of prostate cancer,” Dr. Haley Luxton, who studies the impact of prostate cancer in the UK, explains. “I refer to them as ‘pussycats’ and ‘tigers.’ Pussycats are the slow-growing types, which typically do not lead to death.”

“On the other hand, tigers are highly aggressive forms of prostate cancer, and these men require immediate treatment to prevent mortality.”

Autopsy research indicates that over 50% of men over 90 have prostate cancer cells, many of whom were never diagnosed during their lifetime.

“Most men will eventually have prostate cancer cells,” adds Dr. Cody Watling, a postdoctoral researcher at the National Cancer Institute. “However, whether it becomes clinically significant—causing symptoms or spreading—is an entirely different issue.”

Three Key Risk Factors

What really increases your risk of prostate cancer?

According to science, there are three major factors—sadly beyond your control:

Age – The risk increases significantly after age 50, with most diagnoses occurring in men over 70.
Ethnicity – Black men are twice as likely to develop prostate cancer as their white counterparts. The reasons remain unclear, although genetics may play a role.
Family History – If your father, brother, or grandfather had prostate cancer, your risk is elevated—especially if the diagnosis occurred before age 60. The BRCA2 gene is a contributing factor.

Watling notes that these risk variables are generally linked with both prostate cancer and more aggressive forms of the disease. “Evidence suggests that age, family history, and being Black increase the overall risk of aggressive prostate cancer.”

More than 50% of men over 90 have prostate cancer cells, but many are benign. – Getty

Lifestyle Considerations

While some reports suggest that lifestyle choices can reduce risk, the situation is complex.

Watling, who researched diet and prostate cancer risk at Oxford University, stated, “To date, strong evidence has been elusive.”

Some studies indicate a potential link between high consumption of dairy, particularly milk, and slight increases in prostate cancer risk, likely due to a growth factor known as IGF-1. However, Watling emphasized, “The evidence remains ambiguous, and there is no robust connection.” More research is necessary to clarify these relationships.

One possible exception is obesity. “There is some evidence suggesting that being overweight correlates with a higher risk of aggressive or fatal prostate cancer,” says Watling. “However, it’s challenging to determine if this is biological or due to less frequent early screening in heavier individuals.”

Luxton concurs: “Maintaining a healthy, balanced diet and engaging in some form of physical activity—even just a ten-minute walk—can be beneficial.”

Recommendations

If you are over 50, or over 45 with a higher risk (due to family history or being Black), Prostate Cancer UK advises initiating a conversation with your GP.

You can assess your risk in just one minute with the Prostate Cancer UK Online Risk Checker.

Your doctor may then conduct various screening tests, including prostate-specific antigen (PSA) blood tests, examinations, and MRI scans as necessary.

In Conclusion

Joe Biden’s diagnosis understandably alarmed many, but it also led to a surge of misleading or overly simplistic guidance. Here are the facts:

The risk of prostate cancer cannot be entirely eliminated.
Most risks are linked to age, family history, and ethnicity, rather than diet or lifestyle factors.
Nevertheless, healthy habits remain important for reducing the risk of aggressive prostate cancer and other diseases.
If you are at high risk, it’s crucial to speak with your doctor.

About Our Experts

Hailey Luxton is the Head of Research Impact and Engagement at Prostate Cancer UK, tasked with identifying initiatives that can significantly influence the charity’s research program and expedite research projects. Previously, he conducted research at University College London and Cancer Research UK.

Cody Watling is a postdoctoral researcher at the National Cancer Institute. His research has been featured in publications such as BMC Medicine, Clinical Nutrition, and British Journal of Cancer.

Read more:

Source: www.sciencefocus.com

Here’s what we often misunderstand about prostate cancer.

Posted on May 20, 2025 by Igor Mitreski

Joe Biden’s recent prostate cancer diagnosis has brought awareness to these health issues within the public discourse.

Prostate cancer charities are urging men across the country to assess their cancer risk through signs and to seek medical advice if they experience symptoms like frequent and uncontrollable urination. Nevertheless, prostate cancer remains a nuanced and intricate condition.

The prostate gland is located beneath the bladder and typically enlarges with age. The urethra, which drains urine from the bladder, passes through the prostate. Consequently, when the prostate enlarges, it can compress the urethra, impeding urine flow and leading to symptoms such as dribbling and increased urgency to urinate. Overall, this is a prevalent condition.

Likewise, the incidence of cancers originating in the prostate is quite common. Autopsy studies indicate that 36% of white individuals and 51% of African Americans had unreported prostate cancer. In the 1970s, he was diagnosed with prostate cancer.

Photo credit: Getty

Another study suggested that five percent of men under 30 lived with prostate cancer. This may seem surprising, but these cancers were identified during autopsies of men who passed away from other causes. Medical professionals have long maintained certain sayings, such as “That’s how I die from prostate cancer.”

This presents a significant challenge concerning prostate cancer. It can manifest in a form that causes minimal harm while also possessing a variant that is potentially lethal and can metastasize to nearby organs and bones.

How Dangerous Is Prostate Cancer?

Currently, prostate cancer accounts for approximately 35,000 deaths in the U.S. each year, with over 313,000 men diagnosed annually.

The key to addressing this issue lies in identifying which cases pose a threat, as treatments like surgery, radiation therapy, and hormone therapy may have side effects such as long-term erectile dysfunction and incontinence.

It is essential that patients avoid unnecessary treatments that do not benefit them.

Unfortunately, there is currently no straightforward method to differentiate between aggressive tumors and those that are indolent. A blood test known as the PSA (prostate-specific antigen) test was created in the 1990s to monitor men’s responses to prostate cancer treatments.

Following its introduction, the number of diagnosed prostate cancer cases surged, yet there was no corresponding decrease in mortality rates.

This led Richard Alvin, the researcher who developed the PSA test, to remark, “The widespread use has resulted in a costly public health crisis.” This is due to the PSA test potentially generating false positives caused by factors aside from prostate cancer, including infections and benign prostate enlargement.

In the U.S., the Preventive Services Task Force reviews research independently and issues recommendations regarding screening.

They state that PSA screening can marginally lower the risk of death from prostate cancer in some men. However, many men may experience harm from the screening, including false positives leading to unnecessary tests and diagnoses of non-threatening issues.

In short, increased screening rates in the U.S. may have contributed to deteriorating health outcomes for men, as they pursued treatments for conditions detected through positive test results that were not life-threatening.

Despite a reduction in testing rates since their peak in the ’90s, prostate cancer mortality rates in the U.S. have gradually decreased over the years. This might be attributed to improved treatment protocols, rather than indicating benign prostate enlargement. Limiting trials to men who exhibit symptoms of prostate enlargement could prevent unnecessary cancer treatments.

In other regions, such as in Sweden, prostate cancer screening cut mortality rates from 1.7% to 0.98%, although this required diagnosing 13 men to prevent a single death.

What is the Solution?

To mitigate this issue and avoid unnecessary treatments, a “watchful waiting” approach has shown efficacy. A recent 15-year British study indicated that localized prostate cancer with low mortality rates whether treatment included radiation, prostate removal, hormone therapy, or observation. This underscores the futility of invasive treatments offering no significant benefits.

So, what steps can we take? In the UK, the National Screening Committee regularly reviews the recommendation for PSA screening for prostate cancer. Recent research has identified harmful cancers through MRI screenings, but there is still insufficient evidence regarding whether this can reduce death rates while minimizing excessive treatments.

Meanwhile, straightforward messages regarding the benefits of screening are being communicated to men without adequately addressing the potential drawbacks. Numerous screening events are organized by well-meaning charities during sports events. Advocates argue that informed consent is critical; otherwise, we risk offering false promises and ensuring minimal progress in men’s health.

This article was published in 2024

Read more:

Source: www.sciencefocus.com

Doctors say Biden’s prostate cancer diagnosis is unusual, but not unprecedented.

Posted on May 20, 2025 by Igor Mitreski

New information regarding former President Joe Biden’s prostate cancer diagnosis indicates that while his case is not common, it is not entirely unheard of, according to the healthcare professionals who treated him.

At 82, Biden received a diagnosis of aggressive cancer on Friday after a nodule was found in his prostate, his personal staff announced. The cancer has spread to his bones, but his office stated that he is likely to respond well to treatment.

Most prostate cancer diagnoses occur at an early stage through routine screenings, which may include blood tests or rectal exams.

However, approximately 8% of cases have already metastasized to other organs by the time of diagnosis. In such instances, oncologists believe the patient may have had prostate cancer for several years, possibly up to a decade.

“We’ve encountered numerous patients facing significant health challenges,” stated Dr. William Dahoot, chief science officer at the American Cancer Society.

That said, exceptions exist.

“While most prostate cancers are slow-growing, some can develop rapidly and pose a high risk of metastasis,” explained Dr. Aron Weiser, a urologist and chief medical officer. “Is it common? No. But it can occur, dependent on the unique biology of that cancer.”

Screening facilitates early detection, yet there is disagreement among healthcare professionals regarding who should be screened for prostate cancer.

Many physicians refrain from screening men in their late 70s or 80s, as these individuals are generally more likely to die from other medical issues than prostate cancer. Nevertheless, with increasing life expectancies, some doctors consider screening appropriate for healthier older men.

According to the American Cancer Society’s recommendations, men in their 50s and 60s should be screened every two years. Men with elevated levels of prostate-specific antigens—a protein made by the prostate—should undergo annual screenings. Additionally, men at higher risk for prostate cancer, such as African Americans or those with a family history of the disease, should begin screening in their 40s.

However, current guidelines from the U.S. Task Force on Preventive Services, an independent panel that advises on practices often covered by insurance, state that men aged 55 to 69 should only consider discussing blood tests with their physicians. The task force is currently reviewing new screening guidelines for prostate cancer, with many healthcare providers advocating for a broader recommendation.

Weiser noted that there was a broader screening approach in the late 1980s and early 1990s, leading to premature diagnoses and treatments that may not have impacted patients’ lives. The 2012-2018 U.S. Preventive Services Task Force recommended blood tests to help identify prostate cancer, resulting in decreased screening rates.

“Prostate cancer behaves differently; many cases are benign, not causing issues for individuals,” Weiser remarked. “The goal should be to identify aggressive cancers.”

In recent years, there has been a shift back toward increased screening as doctors have improved their understanding of which cases require treatment versus those that should be monitored.

Nevertheless, Dahut expressed ongoing concerns among patients and physicians about whether the benefits of screening outweigh the risks of overdiagnosis and overtreatment. Screening rates have declined steadily since 2012, and Dahut notes that this trend has led to a 5% increase in diagnoses of more advanced prostate cancer.

It remains unclear whether Biden has undergone prostate cancer screenings in recent years. His annual physical examination in February 2024 did not indicate a screening was performed, which is not unusual for someone of his age. A physical exam in 2019 revealed an enlarged prostate but did not lead to a cancer diagnosis at that time.

Dr. David Shusterman, a urologist based in New York, stated that Biden’s advanced diagnosis is atypical among patients who are screened regularly.

“It is rare for metastasis to have occurred in someone who regularly sees a urologist,” he said.

Diagnosis is often more prevalent in individuals who do not maintain regular medical consultations. Rick Gum is one such case; he was never screened before his prostate cancer diagnosis in 2018. Gum, a 73-year-old trucking company owner from Big Rock, Illinois, initially sought care for a hernia but was found to have aggressive cancer that had spread to his bones.

“I learned the hard way,” he remarked. “I should have visited the doctor.”

Gum noted that his cancer was too advanced for standard treatment, prompting his participation in various clinical trials at Northwest Medicine, which included chemotherapy, radiotherapy, and treatments involving radioisotopes.

“I’ve enjoyed seven excellent years since my diagnosis,” he reflected. “They’ve been quality years. I ride motorcycles, travel a bit, and love my work. I’ve been able to do it all.”

According to the American Cancer Society, around 37% of patients with metastatic prostate cancer survive at least five years post-diagnosis.

Dr. Peter Nelson, vice president of precision oncology at the Fred Hutch Cancer Center, mentioned that patients like Biden could have over a 90% response rate to treatments that lower testosterone—a hormone that can promote cancer growth. These hormonal therapies are typically administered through injections or tablets.

“He may start with multiple medications and anticipate several years of effective treatment before any resistance develops,” Nelson noted. Some patients also receive chemotherapy or radiation in conjunction with hormone therapy, he added.

According to sources familiar with the family’s perspective, Biden and his family are exploring “multiple treatment options,” including hormone therapy.

Source: www.nbcnews.com

Approach to Prostate Cancer Diagnosis: Insights from Biden’s Patient Care Strategies

Posted on May 19, 2025 by Igor Mitreski

Prostate cancer specialists assert that former President Joseph R. Biden’s diagnosis is grave. Announced by his team on Sunday, it was revealed that the cancer has metastasized to his bones and is classified as Stage 4, the most severe stage of the illness. This condition is currently incurable.

However, prostate cancer professionals highlight that advancements in the diagnosis and treatment of prostate cancer have significantly improved the outlook for men facing advanced disease, primarily based on research funded by the National Institutes of Health and the Department of Defense.

“We’ve explored numerous avenues for intervention,” remarked Daniel W. Lynn, a prostate cancer specialist at the University of Washington.

Dr. Judd Mull, a prostate cancer expert at Duke University, noted that men experiencing prostate cancer that has spread to the bones can now “survive five, seven, ten years or even longer” with current treatments. In the 1980s, men like Biden might “wish to pass away from natural causes rather than from prostate cancer,” he pointed out.

Biden’s office indicated that he experienced urinary symptoms, which prompted him to seek medical evaluation.

However, Dr. Lin expressed skepticism, stating, “I don’t believe his symptoms were related to the cancer.”

Instead, he suggested that the most plausible sequence was that doctors had examined Biden, discovered a nodule in his prostate, and conducted blood tests and prostate-specific antigen tests. PSA tests detect proteins produced by cancer cells and can follow blood tests and MRIs that indicate cancer.

Currently, Biden and other patients diagnosed with metastatic prostate cancer are in a better situation than past patients. There are approximately ten novel treatments available for the disease that have significantly altered the prognosis.

The primary strategy is to inhibit the testosterone that fuels prostate cancer. When Dr. Muru began his practice as a urologist in the 1980s, this was achieved by surgically removing the testicles. Today, men have the option of two medications administered via injection that prevent testosterone production, alongside oral pills that achieve the same result.

However, these medications alone are insufficient. Therefore, physicians typically add one of several androgen blockers that further suppress testosterone.

Some men receive supplementary treatments such as chemotherapy or radiation, depending on the extent to which the cancer might spread within the bones.

There have also been advancements in diagnostic procedures.

Previously, doctors assessed the degree of cancer in the bones through scans that detected inflammation. Now, they utilize a more precise scan known as the Prostate-Specific Membrane Antigen (PSMA) PET scan. This scan employs a radioactive tracer that binds to markers on the surface of prostate cells, allowing for faster cancer detection. Consequently, men with prostate cancer cells in their bones now often have a considerably better prognosis compared to those who underwent bone scans just a few years ago.

Additionally, there are medications available that block testosterone and others that can target cancer if chemotherapy and radiation therapy become ineffective.

Dr. Lynn pointed out that increased federal research funding, alongside Biden’s initiative to prioritize cancer research, has contributed to these advancements. He noted that Biden was “one of the first presidents to elevate cancer awareness.”

Regarding Dr. Muru, he remarked that men who develop stage 4 prostate cancer are now often filled with a sense of hope.

“There are now even more resources at our disposal,” Dr. Moul added. “The survival rate has nearly tripled in the last decade. The extent of change is truly remarkable.”

Source: www.nytimes.com

Immunotherapy Drugs: A Hopeful Alternative to Invasive Surgeries and Strenuous Treatments for Cancer Patients

Posted on April 27, 2025 by Igor Mitreski

When individuals develop solid tumors in the stomach, esophagus, or rectum, oncologists have established treatment strategies. Yet, these treatments can significantly affect quality of life, leading to outcomes such as stomach and bladder removal, permanent colostomy bags, radiation exposure, infertility from chemotherapy, and lasting bodily harm.

In response, a research team at Memorial Sloan Kettering Cancer Center utilized drugs from GSK to explore a novel approach.

They initiated the study with 103 participants, who represent a small fraction (2-3%) of cancer patients with tumors ideally suited for immunotherapy—drugs designed to bypass obstacles that prevent the immune system from attacking cancer cells.

Notably, clinical trials do not generally expect immunotherapy to replace standard treatments. Researchers, led by Dr. Lewis A. Diaz Jr. and Andrea Cerseck, opted to administer dostarlimab, an immunotherapeutic agent.

The outcomes were unexpected and offered hope for a select group of patients faced with these cancers.

In 49 patients with rectal cancer, tumors vanished and did not return after five years. Among 54 patients with other cancers—including esophageal, liver, endometrial, urinary tract, and prostate cancers—35 experienced total tumor disappearance.

Out of the 103 patients, only five experienced a recurrence of cancer. Three were given three doses of immunotherapy, while one was discontinued after the tumor reappeared in the lymph nodes. Currently, the four patients show no signs of disease, while the fifth received further immunotherapy to reduce the tumor size.

On Sunday, investigators presented their findings at the American Cancer Research Association’s Annual Meeting, with a paper featured in the New England Journal of Medicine.

Dr. Bert Vogelstein, an oncologist at Johns Hopkins in Baltimore, termed the results “groundbreaking.”

The drug development’s early stages were conducted in his lab, where he expressed surprise at the advancements.

“The concept of treating large tumors from various organs without surgery seemed like science fiction 20 or 30 years ago,” he noted. However, he emphasized that these discoveries stemmed from decades of foundational research.

The reason immunotherapy succeeded for these significant tumors lies in their gene incompatible repair mutations, which obstruct the correction of DNA damage. This leads to tumors accumulating abnormal proteins that signal the immune system for destruction. Nevertheless, the tumors deploy a shield to fend off immune attacks, which immunotherapy can stimulate, enabling the immune system to target the tumors effectively.

For patients like those in this study, Dr. Michael Oberman, a gastrointestinal cancer specialist at MD Anderson Cancer Center in Houston, suggests the results point towards immunotherapy as an option free of chemotherapy, radiation, or surgery.

However, obstacles remain. The drug is priced around $11,000 per dose, requiring patients to undergo nine infusions over six months. To qualify for insurance coverage, it needs inclusion in clinical guidelines established by professional organizations.

The drug is approved for treating uterine cancer with mismatch repair mutations and is also listed in clinical guidelines for rectal cancer, based on previous small-scale studies. Yet, Dr. Diaz indicated that other cancer patients may face challenges in taking the medication. Nonetheless, Memorial Sloan Kettering continues to recruit participants for clinical trials, meaning those with eligible tumors can access the drug at no cost.

For some individuals, immunotherapy is life-transforming. Side effects can occur, with the study noting fatigue, rashes, and itching as the most common. Rare side effects included pulmonary infections and encephalitis.

Maureen Sidris, a 71-year-old from Amenia, New York, discovered she had cancer after struggling to eat a burger.

“It wouldn’t go down,” she recounted, realizing there was some blockage. Ultimately, it was identified as a tumor at the junction of her stomach and esophagus.

In 2019, she visited Sloan Kettering, where her surgeon advised that surgery, chemotherapy, and radiation were mandatory and that surgery would be complex.

However, due to her tumor’s mismatch repair mutation, she was able to join a clinical trial. Her first injection occurred on October 14 of that year, and by January, her tumor had disappeared. While Sidris experienced one side effect from the treatment requiring medication to support her kidney function, she considers it worthwhile to avoid the challenging treatments initially suggested.

“It was indeed a journey,” she remarked. However, she reasoned that she had everything to gain and nothing to lose by trying immunotherapy.

“If it didn’t succeed, I still had surgery as a backup,” she concluded.

Source: www.nytimes.com

ICE detains Harvard scientists analyzing images that could alter cancer diagnosis

Posted on April 22, 2025 by Igor Mitreski

Harvard Medical School’s cutting-edge microscopes have the potential to revolutionize cancer detection and lifespan research. However, a scientist who developed computer scripts to extract maximum information from the images found herself in immigration detention for two months, jeopardizing significant scientific advancements.

The scientist in question is 30-year-old Russian-born Xenia Petrova, who worked at Harvard’s renowned Kirschner Institute until her arrest at Boston Airport in mid-February. Currently detained at the Richwood Correctional Center in Monroe, Louisiana, Petrova is fighting against deportation to Russia, where she fears persecution and imprisonment due to her participation in protests against the conflict in Ukraine.

The incident involving Petrova and the detention of scholars across the country have hindered American universities’ ability to attract and retain crucial talent, a concern raised by Petrova’s colleagues. In fields where expertise is highly specialized, the loss of talent could have grave global implications for the future of medicine and scientific discovery. Scientists and faculty members are contemplating leaving institutions nationwide out of fear that their visas may be revoked or impacted by immigration enforcement actions.

“It’s like a meat grinder,” Petrova, as per a person talking to NBC News from the Louisiana facility, described her situation. “We are all in this system, regardless of having a visa, green card, or a valid reason.”

Petrova’s first immigration court hearing in Louisiana is scheduled for Tuesday morning, where she expects more clarity on her asylum case. Dr. Leon Peshkin, a prominent research scientist at Harvard University’s Faculty of Systems Biology and Petrova’s supervisor, received a call from Customs and Border Protection on February 16, notifying him of Petrova’s detention at Logan International Airport for failing to declare a sample of frog embryos used in research.

International researchers are increasingly anxious about the Trump administration’s strict stance on illegal immigration, with concerns that these policies could deter other foreign scientists from coming to Harvard. Recent surveys indicate a significant portion of scientists are contemplating relocating to Europe or Canada due to actions taken by President Donald Trump.

content omitted for brevity

Surprising increase in colorectal cancer diagnoses among individuals under 50

Posted on March 4, 2025 by Igor Mitreski

Immediately after my 54th birthday, I received the package. The enclosed instructions said the next time I empty my intestines, I should shave a little of the stool, shave it into a small sample bottle, seal it in a prepaid envelope and drop it in a post. I did the act and a few weeks later I was invited to the hospital. My sample contained blood. Colonoscopy was ordered to rule out colorectal cancer.

Thankfully, I don’t have colorectal cancer. Colonoscopy of 54 is not a classic start to middle age. However, over the next few years, this particular rite of passage may begin to occur much earlier. The proportion of this cancer among people in my age group has been declining thanks to screening programs like this, but talking about under 50 years is much more troubling.

Early onset colorectal cancer (EOCRC) is now the circumstance, as is known in people under the age of 50, due to its virtually unprecedented nature of the 20th century. 10% of all new cases worldwide. That number is expected to more than double by 2030, and by then EOCRC is expected to be the most common form of fatal cancer among Americans aged 20-49.

The reasons are uncertain, but ambitious new projects explore potential causes. The idea is that EORC may also be a more clear and aggressive form of illness. Meanwhile, as routine screening expanded to younger groups – in January, the UK reduced the screening age to 50 – and the new, less invasive test…

Source: www.newscientist.com

Big animals face heightened cancer risk, yet enhanced defenses have emerged

Posted on February 25, 2025 by Igor Mitreski

African elephants have extra copies of genes that help resist cancer

Neil Aldridge/Nature Picture Library/Aramie

Larger animals live longer and have more cells, and are expected to be at a higher risk of developing cancer. A comprehensive analysis of 263 species suggests that this is true, but also finds that some large animals have evolved ways of reducing risk.

“We provide the first empirical evidence that there is a link between body size and cancer prevalence, meaning that larger species increase cancer than smaller species. “I say it. George Butler University College London.

The results are in contrast to previous studies found. There is no link between weight and cancer rate. But many of these were related to just a few dozen species, Butler says.

To gain a broader view, Butler and his colleagues analyzed data on the size and cancer rates of 79 bird species, 90 mammal species, 63 reptiles and 31 amphibians. The data comes from previous studies by other researchers who sifted through autopsy records that record whether a breeding animal stored in a place like Zoos or an aquarium had cancer when it died. .

The team found that smaller animals were slightly more likely to have cancer than fewer animals at the time of death. Each 1% increase in body weight was associated with an average increase of 0.1% in cancer rates between birds and mammals. Because body mass data were not available in reptiles and amphibians, the team used body length and found that it was associated with an average increase in cancer rate of 0.003% for every 1% increase.

Butler and his team say their discoveries will challenge a long-standing idea known as the Pete Paradox. on the other hand, Veragolbunova At the University of Rochester in New York, the weak correlation still needs explanation.

“The increased risk they see is very, very minor and not proportional to their body size,” she says. “If you take small animals like mice and humans are 100 times larger, or elephants are 100 times larger, the difference in cancer rates is not 100 times higher in humans and 1000 times higher in elephants.”

It suggests that larger species have evolved more ways to protect themselves, Golbunova says.

Indeed, by using evolutionary trees to infer evolutionary rates of animal body size, the team said that if the size increases more rapidly during evolution, birds and mammal species of similar sizes can be We found it to provide better protection against cancer.

Previous studies have identified genetic adaptations in elephants and whales, protecting against cancer by improving DNA repair and preventing broken cells from dividing.

A deeper understanding of how some animals resist cancer can lead to new treatments for people, says Golbunova. “In these cancer-resistant animals, there are specific biological pathways of different fine-tuning, for example, targeting these pathways and then killing cancer cells more efficiently, or perhaps killing cancer cells. You can even prevent cancer from occurring,” she says.

“As these mechanisms have been tested over millions of years in the course of evolution, they are likely to become highly promising drugs,” she says.

topic:

Source: www.newscientist.com

Early trials suggest mRNA vaccines hold potential for treating pancreatic cancer

Posted on February 20, 2025 by Igor Mitreski

Personalized mRNA vaccines, including those for pancreatic cancer treatment, are currently in phase 1 of clinical trials. The research was recently published in Nature.

Pancreatic cancer has one of the lowest survival rates among cancer types, with less than 13% of patients surviving beyond five years after diagnosis. The disease is often diagnosed at an advanced stage, with nearly 90% of cases already progressing when detected.

Pancreatic cancer cells have a high tendency to spread rapidly to other parts of the body, usually after the primary tumor has grown large. Symptoms typically only appear in late stages, and there are currently no routine screening methods like mammograms or colonoscopies for this cancer.

Effective treatments for pancreatic cancer are limited, with survival rates remaining around 10% despite the best available therapies. The development of personalized mRNA vaccines for cancer treatment aims to change this narrative.

Before the widespread use of mRNA vaccines for Covid-19, researchers were exploring their potential for cancer treatment. These vaccines work by training the immune system to identify and attack cancer cells, essentially turning the body’s immune response into a cancer-fighting mechanism. Current research is focused on melanoma, colorectal cancer, and other solid tumors.

The success of mRNA cancer vaccines relies on generating a robust response from T cells, a type of immune cell that recognizes and fights off intruders. These T cells need to be durable and capable of detecting and eliminating cancer cells, including those in pancreatic cancer which present unique challenges due to limited mutation targets.

A recent clinical trial evaluated the efficacy of an mRNA vaccine in pancreatic cancer patients who had undergone surgery to remove the tumor. Results showed that the vaccine elicited a response in half of the participants, generating tumor-targeting T cells that persisted for years. This promising outcome underscores the potential of mRNA vaccines in improving outcomes for pancreatic cancer patients.

The study also highlighted the need for further research to determine the long-term impact of these vaccines on patient outcomes. The development of ready-made mRNA vaccines that target common mutations in pancreatic cancer tumors is another area of ongoing investigation, offering a more standardized approach to treatment.

Overall, early findings suggest that mRNA vaccines hold promise in enhancing the body’s immune response against pancreatic cancer, offering hope for improved survival rates and outcomes in the future.

Source: www.nbcnews.com

What is the best time to take cancer medication?

Posted on February 3, 2025 by Igor Mitreski

Every year, scientists around the world offer research to cancer treatment. What if the answer is related to the time when cancer patients are taking medicine? Group of German scientists wanted to find out if a 24 -hour clock of the body was also known as itself. Approximately rhythmIt can affect the fight against cancer.

To test their hypothesis, scientists monitor how cancer cells behave with various drugs at various times. First, they collected a variety of cells from human milk cancer patients, including some healthy tissue cells and several tumor cells. They thoroughly monitored cell characteristics such as growth, drug reactions, and outline rhythm strength. They explained that the intensity of the rhythm of the day refers to cells that usually change the movement determined by the day and night cycle.

Scientists used the method called to determine the rhythmic intensity. Self -correlationWe measured how cells work at different times. They used the second method to identify the dominant frequency and time of the cellular signal. Continuous wavelength conversion。 They use this method to break down the signals into small parts, each represents different frequencies and time range.

Finally, they use another method to simultaneously look at both large and small cell processes and further disassemble the signals called. Multi -election analysis。 By combining these methods, we measured how the drug affected the growth of cells over time, and identified what has changed based on time -dependent or dunning effects.

Researchers have grown a group of special breast cancer cells, which are known to have biological watches incorporated in the controlled environment. They added drugs to fight a variety of cancers at different times of the day, and evaluated how they changed their effectiveness. They also administered a variety of drugs and found the best dosage for their daily time. In order to test how the cells react over time, the cell growth rate was measured by imaging with a microscope and growing fast under various conditions. Later, scientists organized cells and drugs into groups based on how they responded to the test.

In addition, researchers conducted tests to measure the efficiency of the administered drugs. First, we used a series of light dark cycle to synchronize the cells to a specific outline. Later, they used live cell imaging to monitor cell growth and survival, and administer drugs at a different period of one day, exceeding four hours. After that, the team compared the way cells react to drugs on various occasions and identified the best time to administer drugs for cancer treatment. Scientists have discovered a strong correlation between the aid clock and drugs.

In order to explore the influence of the outline clocks on cell treatment, scientists also tested the overall contribution of each gene component in cells to the overall drug reaction. They explained that the gene of our body decides how well the drug can suppress cancer and how strongly it can accept the drug. However, with almost 20,000 gene, scientists want to match each drug to the most effective target gene.

To do this, the team used two methods to collect very large datasets and create called forecasts. Linear discrimination analysis and Main ingredient analysis。 They used these methods to rank the cell gene according to how effectively the cells react to drugs, and identify the mutant pattern between gene. They discovered that different genes show different sensitivity to each drug.

Scientists concluded that the rhythm of the solar cells affects drug sensitivity and effectiveness. They suggested that future workers test other undeveloped gene and confirm that they are sensitive to specific cancer drugs. The team concluded that their results would help scientists to understand how the 24 -hour cycle of the body would affect cancer treatment, which is sensitive to time.

Post view: 35

Source: sciworthy.com

AI enhances radiologists’ ability to detect breast cancer in real-world exams

Posted on January 7, 2025 by Igor Mitreski

Radiologists can benefit from AI assistance

Amelie Benoist/BSIP/Universal Images Group via Getty

Artificial intelligence models can actually help detect cancer and reduce the burden on doctors, according to the largest study of its kind. Radiologists who chose to use AI were able to identify an additional 1 in 1,000 breast cancers.

Alexander Katalinic and his colleagues at the University of Lübeck in Germany worked with about 200 board-certified radiologists to test an AI trained to identify signs of breast cancer from mammograms. Radiologists examined 461,818 women at 12 breast cancer screening centers in Germany between July 2021 and February 2023, allowing each woman to choose whether or not to use AI. As a result, 260,739 patients were examined by AI and a radiologist, and the remaining 201,079 patients were examined by a radiologist only.

Those who chose to use AI were able to detect breast cancer at a rate of 6.7 per 1000 scans. This is 17.6% higher than the 5.7 cases per 1000 scans for people who chose not to use AI. Similarly, when women diagnosed with suspected cancer underwent a biopsy, women diagnosed with AI were 64.5% more likely to undergo a biopsy in which cancer cells were found. Among women for whom AI was not used, the rate was 59.2%.

The scale of improvement in breast cancer detection with AI is “very positive and exceeded our expectations,” Katalinic said in a statement. “We were able to demonstrate that AI significantly improves cancer detection rates in breast cancer screening.”

“The goal was to show noninferiority,” says Stefan Bank of Vara, an AI company also participating in the study. “If we can prove that AI is as good as radiologists, it becomes an interesting scenario where we can reduce the workload. We were surprised that we were able to show an advantage.”

Over-reliance on AI in healthcare is a concern for some, as it risks missing signs of symptoms and could lead to a two-tiered treatment system where those who can pay are afforded the luxury of human touch. are. Radiologists spent less time examining scans that the AI had already suggested were “normal,” meaning cancer was unlikely to be present, and scans that the AI could not examine took an average of 16 seconds to examine. In contrast, there is some evidence that radiologists spend less time performing exams. Not classified. But these latest discoveries have been welcomed by those who specialize in the safe implementation of AI in healthcare.

“This study provides further evidence of the benefits of AI in breast cancer screening and should be a further wake-up call for policymakers to accelerate the adoption of AI,” she said. Ben Glocker At Imperial College London. “The results confirm what we have seen time and time again: With the right integration strategy, the use of AI is safe and effective.”

He welcomes the study's ability to empower radiologists to make their own decisions about when to use AI, and hopes to see more testing of AI in a similar way. . “This cannot be easily evaluated in the lab or in simulations, and instead we need to learn from real-world experience,” Glocker says. “The technology is ready. We need policies to follow now.”

topic:

cancer /
artificial intelligence

Source: www.newscientist.com

The incidence of colorectal cancer is increasing in young populations globally

Posted on December 12, 2024 by Igor Mitreski

It’s not entirely clear why colorectal cancer is increasing among adults under 50

Steve Gschmeisner/Science Photo Library

SEI 232808754 — It’s not entirely clear why colorectal cancer is increasing among adults under 50

Steve Gschmeisner/Science Photo Library

The incidence of colorectal cancer in young adults is increasing worldwide, but this trend appears to be most prevalent in high-income countries.

Previous studies have shown that the incidence of bowel or colorectal cancer is increasing. Over the past few decades, it has increased in this age group in Western countries, including the United States, Canada, Australia, and the United Kingdom. This has led to speculation that Western lifestyles, including a diet high in meat and processed foods, may be to blame.

To better understand the extent of the problem, song hyunah Researchers from the American Cancer Society in Atlanta, Georgia, and colleagues looked at the incidence of colorectal cancer in 50 countries and territories around the world. They typically used the World Health Organization’s database to collect data on incidence rates from 1975 to 2017, although some countries started reporting this information several years after 1975. Ta.

The research team found that the incidence of colorectal cancer among people aged 25 to 49 is rising in 27 countries and territories. These also include non-Western countries such as Japan and less wealthy countries such as Turkey, raising the possibility that Western lifestyles are not solely behind this trend.

The increase is also unlikely to be related to improved screening tests, the researchers said in the paper, as most countries do not routinely test people for colorectal cancer until age 50.

However, all 27 countries and territories have high or very high scores on the United Nations Human Development Index, which is based on life expectancy, education level, and per capita income.

Additionally, all but six are considered high-income earners, according to the World Bank. Unlike most of the high-income countries studied, in these six countries, cases of colorectal cancer among older people are increasing at the same or faster rate than among younger people.

“I think there’s still evidence of trends that economic development and westernization of lifestyles are really having an impact,” he says. Andrew Chan The Harvard University researchers noted that many countries are adopting aspects of this lifestyle as their economies grow. for example, Japanese meat intake It increased more than seven times between 1961 and 2021.

“Having said that, I think we need to take into account the fact that there are probably other factors at play, such as environmental contaminants,” Chan says.

The researchers note that their study has several limitations, the most obvious being that countries in Africa, Asia and small islands were underrepresented. For example, only one African country was included: Uganda. Some countries did not have complete datasets. For example, India’s figures represent only 4 percent of the population.

Still, these findings could improve our understanding of how colorectal cancer incidence varies in many countries and help devise new ways to prevent the disease, Zhang said. say.

topic:

Source: www.newscientist.com

Shared DNA Mutations Impacting the Genome in Cancer Cells

Posted on December 2, 2024 by Igor Mitreski

The human genome consists of approximately 3 billion DNA base pairs. If these base pairs were letters grouped together on a single line, they would fill more than 6,000 novels, too large to fit in a cell. Instead, some proteins organize and reform DNA into a more functional 3D structure called DNA. chromatin. These proteins regulate how different parts of the genome interact, controlling which genes are activated and which remain silent within each cell. One such protein is CCCTC binding factor or CTCF.

For CTCF to work, it must first bind to a specific spot on the DNA called CTCF. binding site. Scientists report that these CTCF binding sites behave differently in each scenario. Some lose their binding ability due to chemical interactions within the DNA, while others remain stable. Scientists call something stable Persistent CTCF binding site.

Scientists have previously reported that mutations in CTCF binding sites are common in cancer cells and disrupt the normal 3D structure of the genome. However, it was unclear whether these mutations were concentrated at persistence sites or what role they played. Australian researchers sought to understand mutations in persistent CTCF binding sites and how they affect different cancers.

To address these questions, the research team developed a computational tool based on machine learning models. CTCF-INSITE. Their tool uses genetic data and the interactions of organic compounds such as methyl in the genome to predict which CTCF binding sites are likely to persist even as CTCF protein levels decline. Researchers will use this tool to determine which persistent CTCF binding sites across the genome may be particularly vulnerable to mutations and whether these mutations are associated with cancer growth. I mapped it.

Using data from several human cell culture samples, including prostate cancer cells, breast cancer cells, and lung cancer cells, researchers developed a tool that allows them to distinguish between stable and unstable CTCF binding sites. trained. They exploited characteristics such as protein binding strength, the relative location of binding sites within the genome, and how distant regions of DNA interact to produce proteins.

The researchers then looked at mutation data from 12 types of cancer. International Cancer Genome Consortium. To avoid imbalance, we filtered out data entries with too few or too many mutations. Next, we applied CTCF-INSITE. A tool to test whether persistent CTCF binding sites are more likely to mutate in cancer cells than other CTCF binding sites.

They found significantly more mutations in persistent CTCF binding sites in all cancer types examined. This means that there were more mutations at these sites than would be expected by random chance. The researchers noted that the mutations were specific to the CTCF binding site, rather than in parts of the DNA close to it. They also reported that these mutations were more prominent in breast and prostate cancer cells than in other types of cancer.

The researchers also sought to understand whether these mutations alter the 3D structure of the genome. Using experimental techniques such as fluorescence imaging, they examined some of these cancer-specific mutations and found that many of them alter the genome structure and reduce the strength and effectiveness of CTCF binding. It turned out that. They explained that this reduction could affect gene expression in a way that promotes cancer growth.

The researchers emphasized that their findings were not limited to one or two types of cancer, as similar results were found for stomach, lung, prostate, breast and skin cancers. Although the exact mutation patterns vary between cancers, persistent CTCF binding sites were reported to have consistently higher mutations overall.

The researchers concluded that their findings may help other cancer researchers understand similarities in the onset and progression of multiple cancer types. They also proposed that their machine learning tools could provide future researchers with CTCF binding site candidates relevant to experiments investigating undocumented causes of cancer.

Post views: 352

Source: sciworthy.com

Not undergoing traditional cancer therapy, such as that of Elle Macpherson, poses significant risks

Posted on September 5, 2024 by Igor Mitreski

Supermodel Elle Macpherson refuses chemotherapy to treat breast cancer

Australian Press Agency/Alamy

Half of us will develop cancer at some point in our lives, but how many of us can confidently reject mainstream medical advice after consulting dozens of doctors?

In a recent interview Australian Women's Weekly Australian supermodel Elle Macpherson revealed that she did just that, telling the magazine that she was diagnosed with breast cancer seven years ago but refused chemotherapy, opting for an “intuitive, heart-led, holistic approach” to her treatment.

According to the magazine, MacPherson mulled over her decision for weeks after consulting with “32 doctors and specialists,” and finally, in February 2017, she decided to pursue non-pharmaceutical treatment under the guidance of her family doctor, who specializes in “integrative medicine.”

Fortunately, MacPherson is currently in clinical remission, or as she prefers to say, “perfect health.” It's futile to try to assess the risk of her decision to forego chemotherapy without knowing important details about the extent of her cancer, her coexisting risk factors, and the advice she received. For example, she underwent a partial mastectomy, her first surgery to remove a suspicious lump, but Some doctors said That might have been enough treatment.

Nevertheless, the story has sparked outrage online, galvanizing both the growing number of people who distrust “conventional medicine” and those who seek to defend it from growing attacks.

What's behind this distrust? Some researchers say the COVID-19 pandemic “Scientific skepticism” Heated debates are taking place around the world about the severity of the illness, the merits of lockdowns, and the safety of vaccines. More and more Used To hide their anti-scientific views, Conspiracy thinking.

For members of black and minority ethnic communities, Distrust of doctors The reluctance to seek cancer testing and treatment is also being driven by public health and medical institutions. Decades of failure Engaging with them and ensuring equal care in many countries.

In the UK in particular, confidence in the National Health Service's ability to treat cancer has declined. Has fallen in recent yearsand Reports Delaying the start of vital cancer treatment for months.

All of this means that if you're diagnosed with cancer today, your options may seem less clear than they once were. Add to that the typically grueling experience of chemotherapy, and it's no wonder that MacPherson's story of a “non-pharmaceutical” alternative therapy has garnered so much attention.

But it's worth keeping in mind that MacPherson doesn't accurately represent the vast majority of cancer patients. Estimated Net Worth With a net worth of $95 million, she can afford to seek multiple second opinions and even turn down chemotherapy. Her wealth acts as a safety net. Her “ingestible health” company WELCOand her historical romantic ties Disgraced anti-vaxxer Andrew Wakefield,she From 2018 to 2019McPherson's story gets even more complicated.

For most people, refusing medical care carries real risks. 2017 Study Cancer patients who choose alternative medicines as their primary treatment have been found to have a higher risk of dying within five years than those who choose conventional treatments.

Larger studies The following year, he published a study of nearly two million American cancer patients that found that use of complementary medicines was associated with refusal of conventional cancer treatment and a doubling of the risk of death within five years.

Indeed, oncologists More and more Select Use Reduce chemotherapy or avoid it altogether – New treatments, new research The recognition that targeted, customized responses are most effective.

But for now, at least, the advice from organisations like Cancer Research UK is clear: there is no scientific or medical evidence that alternative therapies can cure cancer. At a time when distrust of medicine is widespread, Macpherson's account risks leading people down a dangerous path by trumpeting positive results without important context.

While anyone may be at risk for developing cancer, Macpherson, who was nicknamed “The Body” at the height of her modeling career, had enormous resources at her disposal and was always going to have a better chance than most of us of surviving cancer, regardless of her choices.

Elle Hunt is a freelance writer and journalist.

Source: www.newscientist.com

Breakthrough in cancer treatment: Lab-grown stem cells offer new hope

Posted on September 2, 2024 by Igor Mitreski

Stem cells are produced in the bone marrow and develop into different types of blood cells.

Katerina Conn / SPL/ Alamy

Human blood stem cells have been grown in a laboratory for the first time, which could dramatically improve how certain types of cancer are treated.

The lab-grown cells have so far only been tested in mice, but when injected into the animals, they resulted in functional bone marrow similar to levels seen after umbilical cord blood cell transplants.

Treating cancers such as leukemia and lymphoma with radiation and chemotherapy can destroy blood-forming cells in the bone marrow. A stem cell transplant means new healthy bone marrow and blood cells can grow. The umbilical cord is a particularly rich source of stem cells, but there is a limited amount they can provide, and the transplant may be rejected by the body.

The new method allows researchers to create stem cells from actual patients, eliminating supply issues and reducing the risk that the patient's body will reject the stem cells.

First, they transformed human blood and skin cells into so-called pluripotent stem cells through a process called reprogramming. “This involves temporarily switching on four genes, so that the patient's cells revert to an earlier stage of development that can become any cell in the body,” he said. Andrew Elefanti At the Murdoch Children's Research Institute in Melbourne.

The second step is to turn the pluripotent cells into blood stem cells. “You start by making thousands of tiny, free-floating balls of cells, each containing a few hundred cells, and then you induce them to turn from stem cells to blood vessels to blood cells,” Elefanti says. This process, called differentiation, takes about two weeks and produces millions of blood cells, he says.

When these cells were then injected into mice that lack immune systems, they produced functional bone marrow in up to 50 percent of cases. That means they made the same cells that carry oxygen and fight infection as healthy human bone marrow, Elefanti says. “This unique ability to make all blood cell types over an extended period of time defines them as blood stem cells,” he says.

Abbas Shafi A researcher from the University of Queensland in Brisbane said the work was an “exciting step forward” towards new treatments for blood cancers. “It's never been done before and has great potential for the future.” But even once animal testing is complete, he said a lot of human research still needs to be done before the technique can be used in the clinic.

Simon Cohn Researchers at Flinders University in Adelaide, Australia, say a key advantage of their approach is that it can be scaled up to produce “an essentially limitless supply” of blood stem cells, but they add that the work is based on blood or skin cells, and success rates and blood cell diversity depend on the starting cell type.

“This suggests that treatments are inconsistent even at the preclinical stage in mice, and will need to be addressed before clinical trials in human patients,” he says.

topic:

Source: www.newscientist.com

A Virtual Assistant Revolutionizing Cancer Research Through Interactivity

Posted on July 29, 2024 by Igor Mitreski

Imagine asking your virtual assistant, “Hey Google/Alexa, tell me the lyrics to ‘Beautiful People’ by Ed Sheeran.” Voice User Interface You could possibly receive the information you need within seconds. Cancer doctors and researchers face the challenge of exploring and interpreting cancer genomic data, which resembles a huge library with billions of pieces in different categories. What if you had an Alexa-like tool that could answer questions about the data within seconds?

Traditionally, researchers have used computer programming and interactive websites with point-and-click capabilities to analyze cancer genomic data. Researchers agree that these methods are not only time-consuming, but also often require advanced technical knowledge that not all clinicians and researchers possess. Scientists from Singapore and the United States have collaborated to develop a conversational virtual assistant to navigate the vast library of cancer genomes. They named this assistant Melvin. Their goal was to make relevant information quickly available to all users, regardless of technical expertise.

The scientists described Melvin as a software tool that allows users to interact with cancer genomic data through simple conversations with Amazon Alexa. It incorporates familiar Alexa features, such as the ability to understand and speak everyday English and the ability for researchers to initiate a conversation by saying the name “Alexa.” Additionally, the scientists incorporated a knowledge base containing genomic data for 33 types of cancer from a global cancer database. The Cancer Genome AtlasIt contains a variety of data, including gene expression data, mutations known to increase the risk of developing cancer, etc. It also incorporates secondary information from each database, such as the definition and location of human genes, protein information, and anti-cancer drug efficacy records, to help users effectively interpret the results.

The scientists collected nearly 24,000 pronunciation samples for cancer genes, cancer types, mutations, types of genomic data, and synonyms of all terms in these categories from nine cancer experts at the Cancer Science Institute of Singapore. These experts were from Singapore, Indonesia, Sri Lanka, the United States, and India, which was needed to increase the diversity of Melvin’s accents. The scientists said that due to the lengthy data collection time, the pronunciations did not cover all known cancer genes and traits.

The scientists explained that a voice user interface works well if it correctly hears and understands the user, including the context of the conversation. Because cancer terms differ from regular English vocabulary, the researchers trained Melvin to learn cancer vocabulary using a machine learning process that gives meaning to previously unknown words. Out-of-Vocabulary Mapper Service Design.

Additionally, the researchers developed a web portal where users can submit pronunciations of certain cancer features that Melvin may not initially recognize. This will allow Melvin to know what the user means when he hears those words. To address users’ potential security concerns about the recordings, the researchers noted that users can avoid data storage by deleting the recordings by following the instructions in their Amazon Alexa account. The researchers discussed opportunities to expand Melvin’s capabilities through crowdsourcing for pronunciation improvements. The researchers hope that these pronunciations will provide more data to match regional and national accents so that Melvin can understand and speak.

The scientists say Melvin will work with any device that supports Alexa and will be able to ” Gene Name” and “What percentage of lung cancer patients have a mutation in that gene?” Melvin reported that within seconds it processes these questions and returns responses in audio and visual form.

They also reported being able to ask follow-up questions based on previous conversations. They described the difficulty of getting valuable information from a single question and highlighted the value of Melvin’s ability to maintain context through incremental questioning. The scientists asserted that this design makes it easy for users to explore multiple relevant questions in a single conversation. They also demonstrated that Melvin performs advanced analytical tasks, such as comparing mutations of specific genes across different cancer types and analyzing how gene expression changes.

The scientists concluded that MELVIN can accelerate scientific discoveries in cancer research and help translate research results into solutions that clinicians can apply to patients. They acknowledged that while MELVIN’s framework is currently centered on cancer genes, it can be expanded to support more characteristics of cancer. The team plans to enhance MELVIN by adding more valuable datasets and features based on user feedback..

Post View: 203

Source: sciworthy.com

British General Practitioners Utilize Artificial Intelligence to Enhance Cancer Detection Rates by 8% | Health

Posted on July 21, 2024 by Igor Mitreski

Utilizing artificial intelligence to analyze GP records for hidden patterns has significantly improved cancer detection rates for doctors.

The “C the Signs” AI tool used by general practitioner practices has increased cancer detection rates from 58.7% to 66.0%. This tool examines patients’ medical records, compiling past medical history, test results, prescriptions, treatments, and personal characteristics like age, postcode, and family history to indicate potential cancer risks.

Additionally, the tool prompts doctors to inquire about new symptoms and recommends tests or referrals for patients if it detects patterns suggesting a heightened risk of certain cancer types.

Currently in use in about 1,400 practices in England, “C the Signs” was tested in 35 practices in the East of England in May 2021, covering 420,000 patients.

Published in the Journal of Clinical Oncology, a study revealed that cancer detection rates rose from 58.7% to 66.0% by March 31, 2022, in clinics using the system, while remaining similar in those that did not utilize it.

Dr. Bea Bakshi, who developed “C the Signs” with colleague Miles Paling, emphasized the importance of early and quick cancer diagnosis through their system detecting over 50 types of cancer.

The tool was validated in a previous study analyzing 118,677 patients, where 7,295 were diagnosed with cancer and 7,056 were accurately identified by the algorithm.

Notably, the system’s ability to predict if a patient was unlikely to have cancer resulted in only 2.8% of these cases being confirmed with cancer diagnosis within six months.

Concerned by delays in cancer diagnosis, Bakshi developed the tool after witnessing a patient’s late pancreatic cancer diagnosis three weeks before their death, highlighting the importance of early detection.

“With two-thirds of deaths from untestable cancers, early diagnosis is crucial,” Bakshi emphasized.

In the UK, GPs follow National Institute for Health and Care Excellence guidelines to decide when to refer patients for cancer diagnosis, guided by tools like “C the Signs.”

The NHS’s long-term cancer plan aims to diagnose 75% of cancers at stage 1 or 2 by 2028, utilizing innovative technologies like the Garelli blood test for early cancer detection.

Decision support systems like “C the Signs,” improving patient awareness of cancer symptoms, and enhancing access to diagnostic technologies are essential for effective cancer detection, according to healthcare professionals.

NHS England’s national clinical director for cancer, Professor Peter Johnson, highlighted the progress in increasing early cancer diagnoses and access to timely treatments, emphasizing the importance of leveraging technology for improved cancer care.

Source: www.theguardian.com

Obesity directly correlated with increased risk of breast cancer, say researchers

Posted on April 18, 2024 by Igor Mitreski

Reading time: 7 minutes

Breast cancer affects thousands of people each year. Scientists have shown that many factors can influence breast cancer, including age, physical inactivity, and obesity. However, it is unclear exactly how obesity and breast cancer are related.

Previous researchers have shown that tissue inflammation in obese patients is related to cancer. Other researchers have shown that obese patients have the following characteristics: specific genetic mutations It is also related to cancer. However, how this mutation acts to generate different types of tumors is not fully understood.

Ha-Linh Nguyen and colleagues recently investigated the relationship between breast cancer and obesity. Nguyen and his team wanted to determine how obesity affects breast cancer by examining the tissue cell and genetic profiles of breast cancer in obese patients. Their goal was to see if doctors could develop more targeted treatments for breast cancer based on the genetic mutations involved.

They collected genetic data from the tumors of more than 2,000 breast cancer patients collected during multiple large-scale breast cancer studies conducted by five accredited cancer research institutions. To ensure that no changes had occurred in the breast tumors, the researchers only used data from patients who had not yet started cancer treatment.

The researchers defined obesity based on the patient’s weight-to-height ratio. body mass index, or BMI. They used patients’ BMI data to classify patients into three categories: obese, overweight, and underweight. An obese patient, her BMI was over 30 kilograms per square meter (kg/m2).²), the BMI of overweight patients was 25–30 kg/m2.²lean patients had a BMI of 18.5 to 25 kg/m.². For reference, the average BMI for adults is approximately 26 kg/m3.².

Patients were then further categorized based on breast tumor type. These categories include patients with tumors that originate in the milk-producing glands of the breast. Invasive lobular carcinoma tumoror a comparison of patients with ILC tumors and patients without specific tumor types.

The researchers also took into account other biological factors used to identify the type of breast cancer. estrogen receptor. Tumors in patients with estrogen receptor-positive breast cancer contain receptors that use the hormone estrogen to stimulate tumor cell growth. The tumors of breast cancer patients who are estrogen receptor-negative do not contain this receptor.

They also looked at another way to determine the type of tumor, a method called. HER2 factor. HER2-positive breast cancer patients contain a protein called human epidermal growth factor 2, which allows cancer cells to multiply rapidly. The researchers used these biochemical markers to classify patients by tumor type, and then used statistical analysis to distinguish between tumor types in obese patients and those in lean and overweight groups. We compared the types.

Researchers found that in obese patients with non-specific tumors that are estrogen receptor positive and HER2 negative, BMI influences breast cancer in the same way that age influences cancer development. The researchers explained that as we age, the body’s immune response slows down, giving cancer cells more time to accumulate before the body reacts and stops the process. They suggested that these results support the idea that both age and obesity are risk factors for developing breast cancer.

The scientists then looked at whether the tumors in each group had one or more cancer-causing mutations. The research team specifically looked at genes that researchers had previously shown had mutations that cause breast cancer. They also examined tumor DNA to see if there were mutations that caused deletions or amplifications of specific parts of the DNA. Change number of copies.

Researchers found different genetic mutations in patients with different BMIs. They found that a gene involved in cell division signaling, called P1K3CA, was less mutated in obese patients who were estrogen receptor positive, HER2 negative, and had unspecific tumors. Mutations in two other HER genes, CCND1 and CCNE1, were more common in obese patients with estrogen receptor-positive tumors.

The researchers concluded that their study showed a genetic link between breast cancer and obesity. They suggested that some genetic mutations found in tumors of obese patients, particularly CCND1 and CCNE1 mutations, may enable targeted breast cancer treatments. They suggested that future researchers should investigate how the biochemical pathways these genes are associated with actually contribute to breast cancer formation to better develop treatments. .

Post views: 262

original research: Obesity-related changes in the molecular biology of primary breast cancer

research has been published:July 21, 2023

research author: Harinh Nguyen, Tatiana Geukens, Marion Mehtens, Samuel Aparicio, Ayse Bassez, Ake Borg, Jane Block, Anejan Brooks, Carlos Caldas, Fatima Cardoso, Maxim de Schepper, Mauro DeLorenzi. , Caroline A. Drucker, Anuska M. Glass, Andrew R. Green, Edoardo Isnardi, Jörn Eifjords, Hazem Kout, Stian Knapskog, Savitri Krishnamurthy, Sunil R. Lakhani, Anita Langerod, John W. M. Martens, Amy E. McCart-Reid, Lee Murphy, Stefan Nauraz, Selina Nick-Zinal, Ines Nebelsteen, Patrick Neven, Martine Picard, Coralie Ponsetto, Kevin Puni, Colin Purdy, Emad A. Raka, Andrea Richardson, Emile Rutgers, Anne Vincent-Salomon, Peter T. Simpson, Marjanka K. Schmidt, Christos Sotiriou, Paul N. Spann, Kiat. Tee Benita Tan, Alastair Thompson, Stefania Tommasi, Karen van Baeren, Marc van de Wivel, Steven van Leer, Laura van't Veer, Giuseppe Viale, Alan Viali, Hanne Voss, Anke T. Witteveen, Hans Wildyas, Giuseppe Floris, Abhishek D. Garg, Anne Smeets, Dieter Lambrecht, Elia Biganzoli, Francois Richard, Christine Desmet

The research was conducted at the following locations:: Katholieke Universiteit Leuven (Belgium), Lund University (Sweden), Netherlands Cancer Institute (Netherlands), University of Cambridge (UK), Champalimaud Clinical Center/Champalimaud Foundation (Portugal), University of Lausanne (Switzerland), SIB Swiss Institute of Bioinformatics (Switzerland), Antoni van Leeuwenhoek Hospital (Netherlands), University of Nottingham (UK), University of Iceland (Iceland), University Hospitals of Leicester NHS Trust (UK), University of Bergen (Norway), and University of Texas MD Anderson. University of Queensland, Herston (Australia), Royal Brisbane and Women's Hospital, Herston (Australia), Oslo University Hospital, Ullenjausen (Norway), Erasmus University Medical Center, Rotterdam (Netherlands), University of Manitoba , Manitoba Institute for Cancer Treatment (Canada), University Hospital Leuven (Belgium), Jules Bordet Institute and Free University of Bruxelles (Belgium), European Organization for Research and Treatment of Cancer (EORTC) Headquarters (Belgium), University of Dundee (UK) , Nottingham University Hospitals NHS Trust (UK), Johns Hopkins University (USA), Netherlands Cancer Institute (Netherlands), Institut Curie, PSL Research University (France), Radboud University Medical Center (Netherlands), Sengkang General Hospital ( Singapore), National Cancer Center (Singapore), Baylor College of Medicine (USA), IRCCS Istituto Tumouri “Giovanni Paolo II” (Italy), University of Amsterdam (Netherlands), University of Antwerp (Belgium), UCSF Helen Diller Family Institute Cancer Center (USA), European Institute of Oncology IRCCS (Italy), University of Milan (Italy), Synergie Lyon Cancer, Plateforme de Bio-informatique 'Gilles Thomas' (France), Università degli Studi di Milano (Italy)

This research was funded by: Luxembourg Cancer Foundation, European Research Council, University of Leuven.

Availability of raw data: Data from the ICGC cohort includes: ICGC Data Portalthe data from ELBC includes: gene expression omnibus Accession number GSE88770 provides access to data from MINDACT. EORTCindividual patient read count data can be accessed below. bio keythe raw sequence reads include European Genomic Phenomena Archive Research No. EGAS00001004809 and data accession number. EGAD00001006608

Featured image credit: Photo provided National Cancer Institute upon unsplash

This summary was edited by: Aubrey Zirkle

Source: sciworthy.com

Can MRI scans improve the accuracy of prostate cancer screening?

Posted on April 5, 2024 by Igor Mitreski

MRI scans may improve prostate cancer screening accuracy

Skynesher/Getty Images

There is both good news and bad news when it comes to prostate cancer testing. First, the bad news. Blood tests that measure a compound called prostate-specific antigen (PSA) are too inaccurate. As a result, some men end up undergoing cancer treatments they didn’t actually need, causing incontinence and erectile dysfunction.

On the other hand, combining a PSA test with an MRI scan of the prostate can make screening more accurate, especially if double testing is recommended only for people at high risk of tumors. An expert group called the Lancet Committee on Prostate Cancer made this recommendation in a new report.

We certainly need to rethink prostate screening, but will these new proposals succeed in reducing harm?

Prostate testing has long been controversial. PSA is released at high levels by cancerous prostate cells, but is also produced at low levels by healthy prostate cells.

Blood tests were introduced as a way to track the success of cancer treatment. It began being used as a screening test in the 1990s, in part as a result of a campaign by men’s health groups for something comparable to breast cancer testing.

The problem is that PSA alone is not reliable as a screening tool. Levels may rise temporarily, such as after sex, during a urinary tract infection, or while riding a bicycle. Even if the increase continues, most prostate cancers grow so slowly that if left untreated, they will never be noticed or cause any problems.

These problems wouldn’t be so important if it weren’t for the fact that the treatments used to remove the cancer (usually surgery or injecting radioactive material into the tumor) can cause permanent incontinence and erectile dysfunction. It would have been. Biopsies to determine whether cancer is present can also cause these problems.

randomized trial It has been shown that for every 1,000 men who undergo regular PSA testing, one fewer man will die from prostate cancer over a 10-year period, but three will remain incontinent and 25 will remain impotent.

These disturbing figures are forcing health services in most high-income countries, including the UK and Australia, into uneasy compromises. Unlike breast and colorectal cancer tests, no invitations for prostate tests will be sent out, but those who wish to undergo the test can take it if the risks are explained to them.

As a result, higher-income men are more likely to take the PSA test, and lower-income and black men are less likely to be tested, the new report says. This is unfortunate because men of African descent are about twice as likely to develop prostate cancer as men of European descent.

The report’s authors say health systems need to use more sophisticated forms of screening, including both PSA tests and MRI scans. This scan allows your doctor to assess the size of your prostate and identify suspicious areas that may be cancerous.

Something close to this dual method is already in place in some countries, including the UK, where the next step for people found to have high PSA levels is an MRI scan. This means that people who are reassured by their scan results can avoid a more invasive biopsy. “This greatly reduces the problem of overdiagnosis,” he says. nicholas james, a researcher at the Institute of Cancer Research in London and one of the authors of the report.

But James says it may be even better to combine the PSA test with an MRI scan before the results are fed back to avoid men being mistakenly told they may have cancer.

The committee says health care organizations should use this combined approach to launch formal screening campaigns targeting three groups known to be at high risk. Black men, people with a family history of prostate cancer, and men who have a mutation in one of their prostate cancers. BRCA Genes also associated with breast cancer.

This would avoid the current situation where men at low risk are probably getting too many PSA tests, while men at high risk are getting too few or no PSA tests.

The proposal is certainly suggestive, but it remains to be seen whether it will discourage people from getting prostate exams. recently” cure cancer phobia.

The arrival of the PSA test may be like opening a Pandora’s box, James says, but the proposed new approach will likely alleviate at least some of the harm.

topic:

Source: www.newscientist.com

Researchers suggest innovative therapy for stomach cancer

Posted on April 1, 2024 by Igor Mitreski

Cancer cells grow abnormally and are difficult to control. Scientists call this growth on the lining of the stomach stomach cancer. Gastric cancer is a global health concern in the United States, East Asia, and Eastern Europe. There are usually no symptoms at the time of onset, but it often affects people infected with a bacterial species called Helicobacter pylori.

Researchers have found that diagnosing stomach cancer early is difficult, so many people with stomach cancer die within five years of diagnosis. As cancer grows, it moves from the stomach to other organs, such as the kidneys and liver, through a process called metastasis, which increases the severity even further. This problem raises the need for effective early diagnostic and therapeutic targets to combat gastric cancer before metastasis occurs.

Human cells contain molecules that carry genetic information essential for the development and functioning of organs and body systems. This molecule is DNA and it consists of a sequence of four nucleotide bases: adenine, guanine, cytosine, and thymine.

To carry out its role, DNA undergoes two transformations through biochemical reactions. First, it is transcribed into a slightly similar but less stable molecule. RNAIt is a sequence of nucleotide bases that is almost identical to DNA, except that it has uracil instead of thymine. This RNA serves as a template for protein synthesis, and there are various types. Enzymes then convert some of these RNA molecules into in particular messenger RNA or convert mRNA into protein. Proteins allow organs to grow and function.

Not all RNA molecules become proteins. What does not become protein non-coding RNA or ncRNA. These ncRNAs interact with cells and other molecules to control various processes required to form proteins from DNA for cell growth and survival.

In the past, researchers discovered a type of ncRNA called long ncRNA, which affects the body's immune system's ability to fight cancer cells. However, there are no studies specific to their activity in gastric cancer. Therefore, a group of Chinese biomedical researchers investigated how these ncRNAs influence the development of gastric cancer and how scientists can utilize their ncRNAs to predict the survival of gastric cancer patients.

Researchers found that normal and gastric cancer sample from global cancer database called cancer genome atlas. The normal samples were from patients without gastric cancer and served as the standard or reference point for comparison. Using the R programming language and a software package developed for biological data, they investigated which groups of ncRNAs were expressed at different levels in these patients. They used information from a genome browser called ensemble Identify protein-encoding genes located within and around differentially expressed ncRNA regions.

The researchers found that the expression levels of thousands of ncRNAs were different in gastric cancer compared to normal sample tissue. they again, 15 genes surrounding ncRNA regions that influence gastric cancer progression. They found that about 8 out of 10 ncRNAs were expressed at levels higher than those required in normal cells, and the rest were expressed at lower levels.

Additionally, the researchers investigated the time period during which ncRNAs interact with other ncRNAs and mRNAs to influence tumor growth and patient outcomes. They identified five long ncRNAs that interact with mRNA; microRNA. These long ncRNAs caused abnormal increases and decreases in protein levels within cells, influencing differences in tumor development and progression, as well as patient outcomes. They reported one microRNA that could inhibit tumor growth and serve as a potential target during therapy.

They used a statistical method called , to analyze the proportion of cells that fight infections and harmful substances. immune cellswere investigated in cancer and normal samples to determine how each cell interacts with ncRNAs and influences patient survival. The study highlighted that certain immune cells were higher depending on the age and stage of gastric cancer in the patients whose data were obtained. They confirmed the relationship between immunity and long ncRNA regulatory networks in gastric cancer. They identified certain immune cells whose presence increases a patient's chance of surviving stomach cancer, and those whose presence reduces survival.

With this study, the authors hope to identify new potential targets, namely specific immune cells and ncRNAs, to assess patients' chances of recovery and develop effective treatments for them. concluded that further insight into the biological processes involved in gastric cancer was gained. However, the size of the cancer data is much larger than the regular data used for comparison, which may have influenced the results, the researchers reported. They emphasized the need for further research, especially laboratory analysis, to validate the findings.

Post views: 302

Source: sciworthy.com

Does biological sex impact cancer susceptibility?

Posted on March 22, 2024 by Igor Mitreski

Cancer is the leading cause of death in humans, accounting for almost 13% of deaths worldwide. Global Health Observatory by the World Health Organization. Biological males (or those assigned male at birth) account for 56% of cancer-related deaths, while biological females (or those assigned female at birth) account for only 44%.

The researchers showed that these differences between biological sexes are not limited to mortality rates, but are also evident in cancer development, progression, and treatment. For example, in the United States, women have a higher risk of developing breast and thyroid cancers, while men are more likely to develop prostate, colon, and stomach cancers.

Doctors also found that women tend to have colorectal cancer more often on the right side of the body, while men tend to have colorectal cancer more often on the left side of the body. Doctors want to know how biological sex affects different aspects of cancer so they can develop treatments tailored to a patient’s gender.

A team of scientists from Adityunchanagiri Pharmaceutical University in Karnataka state, India recently reviewed research on the role of biological sex in cancer. They explained that because every cell in the human body is controlled by DNA, gender can influence cancer growth at the genetic, molecular, and hormonal levels. Every patient’s biological sex changes the types of hormones and enzymes they produce, as well as the way their bodies respond to and metabolize carcinogens.

Researchers have previously found that men and women have different immune responses to cancer and chemotherapy. Women tend to have stronger immune systems that respond more strongly to cancer than men. The researchers suggested that this discrepancy may explain why fewer women die from cancer.

They also looked at data from doctors treating cancer patients and showed that similar treatments for male and female patients with the same cancer diagnosis resulted in different levels of side effects. For example, female cancer patients experience higher levels of drug-induced toxicity, infection, nausea, and vomiting during treatment than male cancer patients. They found that some anti-cancer treatments can even cause women to develop diabetes.

The researchers concluded that cancer behaves differently in male and female patients. However, despite differences in immune responses and side effects, physicians are still unable to customize immunotherapy treatments for different patients based on their biological sex. They suggested that the typical “one size fits all” approach to cancer treatment could be better tailored to specific cancer patients.

They recommended that drug companies test how new drugs affect male and female cancer patients during clinical trials before the drugs are approved. They suggested that drug companies could use this data to better estimate how much medication male and female patients should take, or for how long. They proposed that treatments tailored to each patient’s biological sex could help doctors treat patients in a more efficient manner with minimal side effects.

Post views: 200

Source: sciworthy.com

Innovative Wearable Device Identifies Early Signs of Breast Cancer

Posted on March 12, 2024 by Igor Mitreski

The World Health Organization reported that in 2020, 2.3 million women worldwide were diagnosed with breast cancer. American Cancer Society states that early diagnosis of breast cancer leads to a 100% survival rate. During the initial diagnosis, images or scans of breast tissue are examined by the doctor to detect abnormalities.

Doctors commonly use ultrasound devices to diagnose breast cancer using sound waves. Ultrasound for diagnosing breast cancer. Scientists have identified limitations of ultrasound in the past, such as the need for proper skills and training, poor contact with skin during scanning, and maintenance challenges of large ultrasound machines in hospitals.

To address these limitations, a group of researchers developed a wearable, portable, and affordable device called cUSBr-Patch, which stands for Compatible Ultrasonic Chest Patch. To create this wearable patch, they used a 3D printer to design a honeycomb-shaped patch with holes that can be attached to a soft fabric bra.

Scientists attached a small scanning device to the patch that uses sound waves to acquire medical images similar to an ultrasound machine. This device, called phased array transducer, uses piezoelectric material and differs from traditional hospital ultrasound scanners, producing clear and high-resolution images.

The cUSBr-Patch is attached to a bra with magnets and allows the patch to directly touch the skin for scanning. A small tracker on the phased array transducer is moved and rotated using a handle to capture images of the entire breast.

Researchers tested cUSBr-Patch on female patients with breast abnormalities, scanning both breasts in six different locations using the phased array transducer connected to the patch. Computer programs were then used to generate images similar to those from standard hospital ultrasound machines.

The researchers concluded that cUSBr-Patch can detect breast cancer at a level comparable to traditional hospital ultrasound equipment. They are working on a smaller version of the device, aiming to make it accessible for home use by high-risk individuals and populations without regular testing facilities to improve breast cancer survival rates significantly.

Post views: 1,152

Source: sciworthy.com

Can fungi be surprising allies in cancer detection?

Posted on March 12, 2024 by Igor Mitreski

Scientists who study cancer have historically focused on understanding the various factors that contribute to cancer development and progression. They have looked at factors such as genes, lifestyle choices, and even bacteria. However, few researchers have investigated the role of fungi in the human body and how they affect cancer.

Researchers in Israel and the United States recently characterized the fungi that live inside human cancer tissue. Researchers took tumor, blood and plasma samples from more than 1,000 of her patients with various types of cancer and performed a type of “DNA sequencing.” ITS2 amplicon sequencing. They used this sequencing method to determine the presence of different fungal species within cancer tissue and measure the number of fungal cells living there.

Researchers found fragments of fungal DNA and cells in tissues from various human cancers. For example, they discovered several types of fungi associated with breast cancer. Cladosporium sphaerospermum, mainly affected patients over 50 years of age. they again, Malassezia globosaa skin fungus that affects pancreatic cancer patients, and Malassezia restriction bacterium, another skin fungus present in breast cancer tissue. Additionally, they discovered the following species: aspergillus and agar medium Found in lung cancer samples, especially those from smoking patients.

The researchers explained that their results were surprising. Skin fungi are not usually associated with breast cancer. Additionally, they suggested: Malassezia globosa DNA found in both breast and pancreatic cancer samples This suggests that it may play a broader role in cancer development.

The scientists then confirmed that the fungus was growing within the cancerous tumor using a method called . tissue staining. Histological staining is like adding color to a black and white photograph. In this case, the photos were of tissue taken from different types of cancer: melanoma, pancreatic cancer, breast cancer, lung cancer, and ovarian cancer. When we stained these tissues, we found that fungi often existed next to cancer cells.

The research team interpreted the results as indicating that fungi can influence cancer progression. They suggested that these fungi may have a commensal or even pathogenic relationship with cancer. In particular, they suggested that the fungus may function as follows. opportunistic pathogensIn other words, they were taking advantage of patients' weakened immune systems to cause infections that would not normally occur in healthy people.

Finally, the researchers used an advanced computational technique known as . machine learning, recognize and identify patterns in DNA data. They wanted to test whether certain types of fungi were present in different types of cancer. Scientists have determined that different types of cancer tissue are inhabited by different fungal communities.

The scientists concluded that understanding the relationship between fungi and cancer could help doctors develop new tools to diagnose and treat cancer patients. In particular, the researchers suggested that doctors could sort the fungal DNA in a patient's blood sample to detect which type of cancer they have. They suggested that fungi may provide a new non-invasive fingerprint for early detection of cancer.

Post views: 798

Source: sciworthy.com

A groundbreaking treatment on the horizon for controlling and preventing cancer

Posted on March 9, 2024 by Igor Mitreski

It is estimated that one in two people will develop cancer during their lifetime. However, advancements in diagnosis and treatment have led to more people surviving cancer than ever before. The question now is, will this trend of increasing survival rates continue, and how close are we to finding a cure?

The trend of improving survival rates is likely to continue, but the discovery of a cure for cancer is complicated due to the fact that cancer is not a single disease, but rather a group of over 200 diseases, each with its own unique characteristics. Despite this complexity, all cancers originate from mutant cells that divide uncontrollably.

While cancer cells evade normal controls on cell division, targeted cancer therapy has emerged as a promising treatment approach. This therapy focuses on inhibiting genetic mutations that drive cancer growth and has shown to be more effective with fewer side effects than traditional treatments like chemotherapy and radiation therapy.

Targeted therapies like hormone therapy and drugs such as imatinib have revolutionized the treatment of certain types of cancer, improving survival rates significantly. The development of new drugs and the repurposing of existing ones have been accelerated by genetic technologies that utilize big data to understand genetic changes driving cancer.

The power of big data

Advances in cancer treatment have been further propelled by genetic technologies and clinical trials that utilize big data to develop new drugs and repurpose existing ones. The Cancer Genome Atlas Project, for example, provides valuable genetic information for various types of cancer, allowing for targeted treatments based on individual genetic profiles.

Credit: Getty Images

While drug treatments have seen significant advancements, immunotherapy has also emerged as a promising approach in cancer treatment. Immunotherapy aims to boost the patient’s immune system to detect and destroy cancer cells more effectively. This field is rapidly evolving, with treatments like immune checkpoint inhibitors and adoptive cell therapy showing promising results.

Vax is on track

Developments in cancer immunization, including mRNA-based vaccines, are changing the landscape of cancer treatment by utilizing the body’s immune system to target cancer cells. Early diagnosis remains crucial in cancer treatment, with advancements in AI technology offering improved diagnostic capabilities.

Prevention is also a key focus in the fight against cancer, with vaccines against infectious causes of cancer such as HPV and HBV showing promising results. Additionally, cancer prevention strategies using drugs or vaccines to eliminate cancer cells before they form detectable tumors are gaining traction.

While a single “cure” for cancer may be unlikely, ongoing advancements in diagnosis, treatment, and prevention offer new hope to cancer patients worldwide. The future of cancer treatment holds the promise of personalized medicine, targeted therapies, and innovative approaches to combat this complex disease.

Read more:

Source: www.sciencefocus.com

Ongoing investigations to determine the reasons behind the rise of colorectal cancer in young individuals.

Posted on March 6, 2024 by Igor Mitreski

Number of people under 50 diagnosed with colorectal cancer has been increasing for 30 years

Mohammed Elamin Aliwi/Alamy

One of the most alarming trends regarding cancer is the increasing incidence of several types of tumors in people under the age of 50, especially colorectal cancer.

A £20m, five-year research project aimed at discovering the causes of the rising number of bowel cancers has been given the green light. The study will use blood, urine and stool samples from millions of people held in about 17 biobanks in Europe, North America and India.

The goal is to determine whether this increase is related to changes in food, drink, medicines, air pollutants, and other environmental chemicals by measuring everything people are exposed to (known as the “exposome”). It’s about understanding what’s going on.

“Exposomes are all the elements of the outside world that influence our health,” he says. Andrew Chan co-leader of the project at Massachusetts General Hospital in Boston;

The number of people under the age of 50 diagnosed with colorectal cancer has been increasing for 30 years. In the UK, for example, these tumors have increased by about 50 per cent in people aged 25 to 49 over this period, and similar trends are seen in the US, Canada, Australia and some European countries.

Nine out of 10 tumors occur in older people, so the increase in deaths among people under age 50 has not yet had a significant impact on the total number of cancer deaths. But this trend is worrying to doctors, especially since tumors in younger people tend to be more aggressive and diagnosed at a later stage.

Speculation abounds as to the cause, but various aspects of modern diets, including increased consumption of processed foods and red meat, and a lack of fiber, as well as antibiotic use and exposure to pollutants, are likely to be contributing factors. It is believed that this is the main cause.

In a new research projectChan and his team have attempted to identify and measure all the chemicals in medical samples obtained in previous studies, and plan to investigate further.

They will use mass spectrometry to identify the chemical signatures that disrupted the levels of novel compounds and natural biochemicals that entered the body.

One of the biobanks being used is Nurses’ Health Study 3, a large-scale project in the United States that charts the health and lifestyles of hundreds of thousands of nurses. Some participants have provided not only blood samples but also stool samples, which will allow the team to analyze gut bacteria as well.

Another important cohort is the Danish Newborn Screening Biobank. The biobank contains dried blood spots from almost every baby born in Denmark since 1982, representing approximately 2 million samples. This will allow researchers to see whether what we are exposed to in the womb is associated with an increased risk of colon cancer.

If, as expected, a correlation is found between certain biochemicals in the blood and the risk of colon cancer, the researchers will investigate whether blood tests can identify people who are more vulnerable. says Mr. Chan. “That could be a group of people who would be targeted for more intensive colon cancer testing,” he says.

Another part of the project will test whether reversing blood characteristics associated with colorectal cancer reduces people’s risk of developing the tumor. Jordana Bell Professor at King’s College London and one of Chan’s collaborators. “We seek to apply the insights we generate early by identifying putative causal factors, understanding potential mechanisms, and designing intervention trials,” she says.

Ian Fawkes from Cancer Research UK (CRUK) said: “In the United States, recent data show that people born in the 1990s have a 2.4 times higher risk of colon cancer than people born in the 1950s. Most cancer cases occur in people over age 50. “This development is an important issue for us to address. The key is to understand why the rise in early-onset cancers is occurring in the first place.”

CRUK is funding the research along with Maryland’s National Cancer Institute, France’s National Cancer Institute and the UK’s Gut Babe Foundation.

topic:

Source: www.newscientist.com

Misconceptions about prostate cancer: What we need to know

Posted on February 24, 2024 by Igor Mitreski

Recent news about King Charles’ prostate issues and subsequent cancer diagnosis has raised awareness of such health issues nationwide. Although the king is not diagnosed with prostate cancer, his efforts to raise awareness among older men have been widely appreciated.

The charity Prostate UK is using billboards to encourage men across the country to assess their cancer risk and consult their GP if they experience symptoms like frequent or difficult urination. However, prostate cancer is a complex and subtle condition.

The prostate, located below the bladder, tends to enlarge with age. The urethra, the tube draining urine from the bladder to the outside, passes through it. When the prostate enlarges, it can put pressure on the urethra, causing symptoms like dribbling and increased frequency of urination. This condition is quite common.

Similarly, prostate cancer is also common. Autopsy studies show that 36% of whites and 51% of African Americans develop prostate cancer in their 70s. There are even cases of prostate cancer found in 5% of men under 30 in autopsy studies. However, not all forms of prostate cancer are equally dangerous, with some being harmless and others potentially fatal.

How dangerous is prostate cancer?

Prostate cancer accounts for around 4% of male deaths in the UK, with approximately 12,000 people dying from it each year. The challenge lies in finding treatments that do not cause further harm, as treatments like surgery and radiation therapy can lead to side effects such as erectile dysfunction and incontinence.

The lack of an accurate way to differentiate between aggressive and non-aggressive tumors is a major problem. The PSA test, developed in the 90s, was introduced to monitor men’s response to prostate cancer treatment. However, the increasing number of diagnoses did not correspond to a reduction in mortality rates.

In the US, the Preventive Services Task Force has offered recommendations for or against PSA screening. While screening may slightly reduce prostate cancer deaths, it can also lead to unnecessary testing and treatments for non-fatal conditions.

To avoid unnecessary treatment, the “watchful waiting” approach has been effective in managing localized prostate cancer with low mortality rates. In the UK, the National Screening Committee does not recommend PSA screening for prostate cancer.

Research suggests that identifying harmful cancers through prostate screening MRI scans may be a viable solution, although more evidence is needed to assess its impact on reducing deaths without overtreatment.

Read more:

Source: www.sciencefocus.com

Increased Cancer Risk in Relatives of Men with Infertility

Posted on February 22, 2024 by Igor Mitreski

The study looked at men who produced less than 1.5 million sperm per milliliter of semen, which is considered to produce very few or no sperm.

Joshua Resnick/Shutterstock

Relatives of men who have infertility problems may be at increased risk of cancer, and the odds vary widely from family to family.

Research suggests that certain relatives within three generations of such men are more likely to develop a variety of cancers, including cancers that affect the colon, testicles, and uterus. However, the risk varies by family lineage and whether the man is infertile or subfertile.

Male infertility has been linked to multiple health problems; cardiovascular diseases etc.. Previous research has also pointed out the following: Association between male infertility and increased cancer risk in relatives of such men.

Joey Ramsay Researchers at the University of Utah in Salt Lake City suspected this might vary from family to family. To find out, they analyzed the sperm counts of 360 men who produced fewer than 1.5 million sperm per milliliter of semen and 426 men who produced no sperm at all. These men were matched in age to more than 5,600 of his others with whom he had at least one biological child. Researchers do not know whether any of the participants were transgender.

Next, they obtained information on cancer diagnoses in the men's first-, second-, and third-degree relatives from Utah's database.

The research team found that relatives of men with low sperm counts within three generations were more likely to develop colon and testicular cancer compared to the general population, and some of those related to men with low sperm counts They discovered there was a high chance of developing sarcoma, Hodgkin said. Lymphoma, cancer of the uterus and thyroid. Both of these groups had much higher rates of bone and joint cancer than the general population.

The researchers then used specially developed software to determine the increased risk of cancer combinations in 34 body regions within different families (both fertile and infertile groups). We have detected a tendency to This resulted in “clustering” that allowed trends within families to be detected.

Two-thirds of male relatives who did not have sperm were at no higher risk of cancer than the general population. However, other families showed a significantly increased risk of various types of cancer, and that risk varied by family lineage, with higher risks for childhood, adolescent, and young adult cancers. There were people too.

Relatives of men with low sperm counts all had an increased risk of at least one type of cancer compared to the general population, but the degree of risk and type of condition varied.

It is unclear why this increased risk occurs, but it may be due to genetic factors or common environmental exposures among relatives. It is hoped that further research will investigate this and lead to tests that identify families at higher risk, Ramsay said.

topic:

Source: www.newscientist.com

Tiny robots may soon navigate human livers to combat cancer

Posted on February 17, 2024 by Igor Mitreski

Science fiction has often depicted microscopic robots, but these tiny machines have become a reality with a wide range of real-world applications such as disease prevention and building repair.

A Canadian research team is now focusing on using these small robots to target liver cancer in various fields. They are working on using them in conjunction with MRI equipment to treat diseases (source).

A series of small biocompatible robots, made of magnetizable iron oxide nanoparticles guided by an external magnetic field, could potentially deliver medical care in a highly targeted manner.

Despite the potential of this technology, it faces a major technical challenge. The gravity of these microrobots exceeds the magnetic force, limiting their guidance if the tumor is located higher than the injection site.

To address this challenge, Dr. Jill Soules, a researcher at the CHUM Research Center at the University of Montreal, developed an algorithm that combines gravity and magnetic navigation forces to guide the microrobots into the arterial branches that feed the tumor.

This research has the potential to change the way liver cancer is treated with radiation therapy, which is the most common type of cancer causing 700,000 deaths annually worldwide.

Dr. Soulez emphasized the advantages of the magnetic resonance navigation technique, indicating that the tumor is better visualized on MRI than on X-ray.

In an experiment using pigs to recreate anatomical conditions, the researchers successfully navigated the hepatic artery branches of the animals and arrived at their destination using the microrobots.

Furthermore, using an anatomical atlas of the human liver, the researchers were able to simulate microrobot maneuvers on 19 patients treated with transarterial chemoembolization, finding that in more than 95% of cases, the location of the tumors matched the navigation algorithm to reach the targeted tumor.

Despite these significant advances, clinical application of this technology is still in the distant future, as artificial intelligence models need further training and improvements for real-time navigation of microrobots to the liver.

read more:

Source: www.sciencefocus.com

Utilizing New Technology to Detect Cancer Early: The Impact on Calderdale and Huddersfield NHS Foundation Trust in West Yorkshire

Posted on December 25, 2023 by Igor Mitreski

A West Yorkshire NHS Trust is utilizing advancements in technology, such as artificial intelligence and surgical robots, to achieve crucial cancer targets and alleviate widespread pressure on hospitals.

Calderdale and Huddersfield NHS The Foundation Trust is meeting three important cancer targets established by the government.

These targets include a waiting time of 28 days for patients who receive an emergency referral and are diagnosed with an infection or cancer, a 31-day wait from the patient’s treatment decision to the first treatment, and a 62-day wait from the emergency GP referral to the first treatment.

Sky News was given a tour of the innovations behind the hospital’s results, starting with a diagnostic test called Cytosponge. The Cytosponge is a small capsule with a string attached that is swallowed by the patient. When dissolved in the stomach, a brush collects cells from the esophageal lining, which are then analyzed for abnormalities.

Cytosponges are used as an alternative to longer and more invasive endoscopies. Patients find the cytosponge less invasive and report a quicker procedure time.

…

Source: news.sky.com

The impact of programmable bacteria on cancer treatment

Posted on December 22, 2023 by Igor Mitreski

Researchers are developing synthetic programmable bacteria to help kill cancerous tissue.Credit: Texas A&M Engineering

https://www.eurekalert.org/news-releases/1009258

https://chat.openai.com/c/6cfb1180-0a40-409b-b230-817e653d2c44

Texas A&M University researchers are co-leading a $20 million project to develop a $1 cancer treatment.

What if a single dose of $1 could cure cancer?

A multi-university research team is receiving federal funding to develop a highly efficient bacterial therapy that targets cancer more precisely and makes treatment safer at a cost of $1 per dose.

Traditionally, cancer treatments have had limited effectiveness in treating patients. Some treatments, such as radiation therapy and chemotherapy, can cause harmful side effects, while others tend to have poor patient response, not to mention the high cost of treatment.Survey results from American Cancer Society Cancer Action Network reports that 73% of cancer survivors and patients are concerned about how they will pay for their cancer treatment, and 51% say they have medical debt from their treatment. For example, cutting-edge cancer treatment can cost up to $1,000,000.

Texas A&M University and the University of Missouri are leading efforts to develop low-cost, safe and controlled cancer treatments. Researchers received a $20 million grant from the Advanced Research Projects Agency for Health (ARPA-H) to fight cancer. The four-year project is part of the current administration’s cancer moonshot plan to boost cancer research and increase funding. It is funded by a newly established agency that aims to accelerate improved health outcomes for all by supporting the development of highly effective solutions to society’s most challenging health problems. It was one of my first projects.

Rapid analysis of cells

$12 million of the grant will go to the Texas A&M Engineering Experiment Station/Texas A&M. Alam Han, Jim Song, and Chelsea Hu are developing programmable synthetic bacteria for immune-induced killing in the tumor environment (SPIKE). The idea is to engineer the bacteria so that the T cells kill the cancerous tissue, and once the cancer is gone, they destroy themselves and are safely excreted out of the body as human waste.

“SPIKE can specifically target tumor cells,” said Han, a professor in Texas Instruments’ Department of Electrical and Computer Engineering. “And because we only target the cancerous tissue and not the surrounding healthy cells, patient safety is dramatically increased. I’m excited to be part of this team tackling a critical health issue that affects so many people. I am very honored.”

Han’s lab is developing high-throughput microfluidic systems that can rapidly process and screen large bacterial therapeutic libraries one cell at a time to rapidly identify the most promising treatments. By fusing microfabrication techniques and biotechnology, these systems create picoliter-scale liquid handling systems that can accurately analyze single cells with high precision and speed, and devices that rapidly analyze individual cells. Realize.

“The big challenge is figuring out how to actually develop these sophisticated microdevices that can run millions of fully automated tests with very little manual or human intervention,” Han said. said. “That’s the engineering challenge.”

Rescue anti-tumor immune cells

While Han innovates and designs microdevices, Song, an immunologist with a background in microbial pathogenesis, T-cell biology, and T-cell-based immunotherapy, has spent the past five years working in bacterial immunotherapy. We are working on this.certain bacteria known as Brucella melitensis At least four types of cancer can be treated by manipulating the human body’s microenvironment and promoting T cell-mediated antitumor immunity.

“We are working on improving Brucella melitensis We can more effectively prevent or suppress tumor growth,” said Song, a professor at Texas A&M School of Medicine. “Our current approach involves finding ways to manipulate bacteria to rescue anti-tumor immune cells and make them more effective at killing tumor cells.

“According to the data so far, BrucellaThe efficiency is dramatically higher than other cancer treatments such as chimeric antigen receptor T-cell therapy and T-cell receptor therapy, with a response rate of over 70%,” said Song.

Safe and controllable treatment

While Professor Song continues to test the effectiveness of bacteria using cancer models, Professor Hu, an assistant professor in Artie McFerrin’s Department of Chemical Engineering and a synthetic biologist, has demonstrated that live bacterial treatments are safe and controllable. We are working to confirm.

” Brucella The strain we are using is attenuated and has been shown to be safe for the host as it lacks key genes required for bacterial virulence,” Hu said. Told. “Ultimately, we want to control the rate at which bacteria multiply within the tumor environment and their ability to self-destruct when their mission is completed.”

To control the rate of growth, the bacteria’s genes are modified to regulate its population, which fluctuates around a certain set point. Hu also plans to incorporate biosensors into the bacteria, allowing them to distinguish between healthy and tumor tissue, allowing them to grow only within the tumor microenvironment.

The bacteria are engineered with receptors that allow patients to take antibiotics after the cancer has gone away. This sends a signal to the bacteria to essentially shred itself and safely remove it from the patient’s body.

“We humans are actually covered in bacteria, and many diseases are caused by imbalances in these bacterial communities,” Hu said. “For example, some people have incredibly fragile stomachs, while others have strong stomachs. The science behind this is that people with strong immune and digestive systems have a healthy gut. It means that it has a population of bacterial cells. There are many possibilities for biological therapy.”

“It’s a really great opportunity to have a great team with the expertise and the ability to push this technology to the forefront,” Hu said. “So the goal is to go into the clinic and provide patients with effective cancer treatment for less than $1 per treatment.”

Tackling difficult problems with unconventional approaches

Other collaborators include Dr. Zhilei Chen of Texas A&M Health Science Center, Dr. Xiaoning Qian of the Department of Electrical and Computer Engineering, and Principal Investigator Dr. Paul de Figueiredo of the University of Missouri.

“The three important advantages of this study are high safety, low cost, and specific targeting of cancerous tumors,” Han said. “We are very excited to be one of the first teams to receive support from ARPA-H, a brand new agency supported by Congress. We take an unconventional approach to tackling difficult problems. High risk, high impact is the hallmark of our approach.”

And the future applications of bacterial engineering that this research unlocks are limitless.

“For our next big project, we will work together to develop bacteria that fight autoimmune diseases such as type 1 diabetes and rheumatoid arthritis,” Song said. Bacteria-based immunotherapy is an exciting frontier in medicine and offers the potential to revolutionize the treatment of autoimmune diseases. With the power of beneficial microorganisms harnessed to modulate the immune system, we are changing the future of medicine. Our research and expertise promises to transform the lives of millions of people, giving them new hope and a healthier tomorrow. ”

Source: scitechdaily.com

Discovery of a direct correlation between elevated insulin levels and pancreatic cancer by scientists

Posted on December 18, 2023 by Igor Mitreski

A new study has proven a direct link between high insulin levels and increased risk of pancreatic cancer in people with obesity and type 2 diabetes. This landmark study shows how excess insulin overstimulates pancreatic acinar cells, leading to inflammation and precancerous cells, particularly in the case of pancreatic ductal adenocarcinoma (PDAC). These findings highlight the importance of maintaining healthy insulin levels and may lead to new strategies for cancer prevention and treatment, including lifestyle interventions and targeted therapies.

For the first time, we explain in detail why people with obesity and type 2 diabetes have an increased risk of pancreatic cancer.

A recent study conducted by scientists at the University of British Columbia’s Faculty of Medicine revealed a direct relationship between high blood pressure and high blood pressure. insulin This level is frequently observed in patients with obesity, type 2 diabetes, and pancreatic cancer.

This study cell metabolismprovides the first detailed explanation of why people with obesity and type 2 diabetes are at increased risk of pancreatic cancer. This study shows that excessive insulin levels overstimulate pancreatic acinar cells, which produce digestive juices. This excessive stimulation causes inflammation and transforms these cells into precancerous cells.

“In addition to rapid increases in both obesity and type 2 diabetes, we are also seeing an alarming increase in the incidence of pancreatic cancer,” said co-senior author and professor in the Department of Cellular Physiology Sciences and co-senior author of the study. said Dr. James Johnson, interim director of the agency. UBC’s Institute of Life Sciences. “These findings help us understand how this is happening and highlight the importance of keeping insulin levels within a healthy range. can be achieved through medication.”

Dr. James Johnson is a professor in the Department of Cellular and Physiological Sciences and interim director of the UBC Life Sciences Institute. credit:
UBC Faculty of Medicine

The study focused on pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer and a highly aggressive disease with a five-year survival rate of less than 10 percent. The incidence of pancreatic cancer is on the rise. By 2030, PDAC is expected to become the second leading cause of cancer-related deaths.

Role of insulin in pancreatic cancer

Although obesity and type 2 diabetes were previously established as risk factors for pancreatic cancer, the exact mechanisms by which this occurs remained unclear. This new study sheds light on the role of insulin and its receptor in this process.

… (content continues) …

Reference: “Hyperinsulinemia causes pancreatic cancer through acinar insulin receptors by increasing digestive enzyme production and inflammation” (Anni MY Zhang, Yi Han Xia, Jeffrey SH Lin, Ken H Chu, Wei Chuan K. Wang, Titine JJ Ruiter, Jenny) CC Yang, Nan Chen, Justin Choa, Shilpa Patil, Haoning Howard Sen, Elizabeth J. Rideout, Vincent R. Richard, David・F. Shafer, Rene P. Zahedi, Christoph H. Borchers, James D. Johnson, Janelle L. Kopp, October 31, 2023. cell metabolism.
DOI: 10.1016/j.cmet.2023.10.003

This study was funded by the Canadian Institutes of Health Research and the Lustgarten Foundation.

Source: scitechdaily.com